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CHAPTER 1 – INTRODUCTION 
 
1.1 Histone Deacetylase (HDAC) Proteins 
1.1.1 Chromatin Structure and Epigenetics 
When Watson and Crick first described the double helical structure of 
deoxynucleic acid (DNA),1 it was only the beginning of the scientific communityʼs 
understanding of the complex structure of DNA and chromatin, and the 
mechanisms involved in gene expression in eukaryotes.  Although chromosomes 
were known to package DNA in the nucleus, it wasnʼt until the late 1970ʼs that the 
role of histone proteins was revealed by Kornberg, who further described the 
structure of chromosomes as double stranded DNA organized around a octamer 
of histone proteins to form the nucleosome.2  The crystal structure of the 
nucleosome published by Luger et al. in 1997 revealed the octamer of histone 
proteins with accessible lysine-rich tails protruding from the nucleosomal core 
and in close proximity to the double stranded DNA coiled (Figure 1.1).3,4  The 
nucleosome structure consists of pairs of histone proteins H2A, H2B, H3 and H4 
associated with 146 base pairs of DNA (Figure 1.1).3  The nucleosomes are 
linked together by a varying length of DNA associated with H1 histone proteins in 
repeating units, which together coil to form the larger structure of chromatin 
fiber.4  These nucleosomal structures are critical for organization of the vast 
amount of DNA into the compact structure of the chromatin in the nucleus of 
eukaryotic organisms (Figure 1.2). 
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Figure 1.1. Crystal Structure of the Nucleosome.  Four pairs of histone 
proteins (H2A, H2B, H3 and H4) form the core of the nucleosome with 146 
base pairs of double stranded DNA wrapped around the histone core.  
Crystal structure from Luger et al.,3 which was then adapted by Kornberg to 
indicate length N-terminal amino tails (dashed lines) and acetylation site 
(lollipops).4  Figure reproduced from Kornberg with permission.4 
 
Chromatin can have two very distinct structures related to the expression 
and repression of genetic material.  Heterochromatin has been described as the 
highly condensed structure that is characterized by silencing regions of gene 
transcription.  Euchromatin is an open-structured chromatin that is characterized 
by transcriptionally accessible regions of DNA.5  Regulation of these chromatin 
structures is essential for proper gene expression, and improper regulation can 
lead to various diseases, most notably cancer (section 1.1.5).  The mechanism 
involved in the conversion between these two chromosomal structures, and their 
corresponding states of transcription, involves a complex myriad of post-
Review
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Figure 2. X-Ray Structure of Nucleosome Core Particle
The disk in Figure 1 is split between the two turns of DNA and viewed from above. Half the core particle, with four histone molecules and 73
DNA ba e pairs, is shown. Three helices from the H3 molecule in the ther half of the c re particle are included in this view at the upper left.
The unstructured histone tails, absent from the X-ray structure, are drawn as dashed lines of appropriate length, with lollipops to indicate
acetylation sites. H2A tails are both N terminal (bottom) and C terminal (top), while tails shown for the other histones are all N terminal.
(Adapted from Luger et al., 1997, courtesy of Luger and Richmond).
of romoters, regulatory elements, and other special Nucleosomes Repress Transcription
Packaging promoters in nucleosomes prevents the initi-sites in DNA (reviewed by Simpson, 1991; Thoma, 1992).
Positioningmay serve to prevent specific protein binding ation of transcription by bacterial and eukaryotic RNA
polymerases in vitro (Knezetic and Luse, 1986; Lorch etto sites within the nucleosome or to potentiate binding
to sites exposed in linkers (see, for example, Straka and al., 1987). Nucleosomes exert a similar inhibitory effect
upon transcription in vivo: turning off histone synthesisHorz, 1991). Positioning may also facilitate the binding
of proteins evolved to recognize DNA sequences lo- by genetic means in yeast, and consequent nucleosome
loss, turns on transcription of all previously inactivecated on the surface of the nucleosome or juxtaposed
by coiling around the nucleosome (see, for example, Lu genes tested (HanandGrunstein, 1988). These andother
observations have led t the conclusion that histoneset al., 1995).
A degree of sequence preference is found also for serve as general gene repressors.
Both histone fold–DNA interactions in the core particleinteraction of the so-called “linker histones,” H1 and its
avian counterpart H5. The main mass of the protein and histone tail interactions in the chromatin fiber are
thought to contribute to repression, and each is counter-binds near one end of the core DNA, which frequently
contains the sequen e AGGA (Travers and Muylder- acted by specific m chanis s. Repression due to inter-
actions in the core particle is opposed by “chromatin-mans, 1996). Neutron diffraction places H1, and thus
the linker DNA, on the inside of the chromatin fiber (re- remodeling” complexes, while that due to condensation
in the chromatin fiber may be relieved by histone acetyl-viewed by Ramakrishnan, 1997), in keeping with evi-
dence that linker histones promote coiling or folding transferase (HAT) and reestablished by histone deacety-
lase (HDAC) complexes. A number of observations sug-of chromatin in the fiber. Histone tails protrudi g from
nucleosomes also appear to promote fiber formation, gest that derepression at the level of the chromatin fiber
precedes that at the level of the individual nucleosome.perhaps by contacting adjacent nucleosomes or by in-
fluencing the configuration of linker DNA (Schwarz et Transcriptionally active genes in vertebrates reside in
chromosomal domains, as large as 100 kb, character-al., 1996). An interaction, seen in core particle crystals
(Luger et al., 1997), of an H4 tail from one nucleosome ized by an elevated rate of digestion by DNase I, in-
creased acetylation of histone tails, and well-definedwith a region of the H2A-H2B dimer on the flat face of
an adjacent nucleosome, could play such a role. Modifi- boundaries (Hebbes et al., 1994 and references therein).
DNase I sensitivity and histone acetylation are more orcations of the histone tails may promote or disrupt these
contacts, controlling fiber formation, and therebymodu- less uniform across a domain, including nontranscribed,
intergenic regions. Thus, these features are not simplylating the accessibility of chromatin for transcription
(Tse et al., 1998). a consequence of transcription, but rather relate to a
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translational modifications to both histone proteins and methylation directly to the 
DNA bases (Figure 1.2).6  Post-translational modifications that are inheritable 
through mitosis, affecting the expression of genetic material without altering the 
DNA sequence, are known as epigenetic modifications.6  While the field of 
genomics studies the DNA sequence, a new field of epigenomics has emerged to 
study the genome-wide chromatin modifications that direct gene expression in a 
given cell type.6  Altered epigenetic patterns during development are responsible 
for cell and tissue differentiation; importantly, the epigenome is responsive to 
external stimuli and is altered in disease states, like cancer6.  The lysine-rich N-
terminal tails of histone are subject to a variety of post-translational modification 
including methylation, phosphorylation, acetylation, ubiquitination (Figure 1.3),7 
sumoylation, and citrullination.8  The reversible acetylation of these lysine 
residues will be discussed in further detail in section 1.1.2. 
 
1.1.2 Histone Acetylation and Deacetylation 
The acetylation state of N-terminal lysine residues on histone proteins can 
play a role in both temporal gene regulation, and also can lead to an altered 
epigenetic state.9  In particular, the acetylation state of the lysine tails of histones 
affects electrostatic interactions between histone proteins and the anionic 
phosphate backbone of the DNA.10  Histone acetylation is promoted by the 
histone acetyl transferase (HAT) proteins resulting in a neutral DNA structure 
(euchromatin), which is accessible to transcriptional machinery (Figure 1.4). 
  
4 
 
 
Figure 1.2.  DNA Packaging Into the Chromosome.  The double 
stranded DNA (purple) is packed into the complex structure of the 
chromosome through interactions with histone proteins (teal). Epigenetic 
modifications such as methylation directly on the DNA backbone (black 
and white) and chemical tags (yellow pentagons) on the histone tails affect 
the structure of the chromosome and the accessibility of specific genes to 
transcription factors.  When the DNA forms tight interactions with histone 
complexes, genes (pink) are not accessible (heterochromatin), while the 
open structure of the DNA allows accessibility of genes (euchromatin). 
This illustration was obtained courtesy of National Human Genome 
Research Institute (NHGRI) (www.genome.gov). 
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Epigenomic Marks. The epigenome can mark DNA in two ways, both of which play a role in turning genes off or on. The first occurs when certain chemical tags called 
methyl groups attach to the backbone of a DNA molecule. The second occurs when a variety of chemical tags attach to the tails of histones, which are spool-like proteins 
that package DNA neatly into chromosomes. This action affects how tightly DNA is wound around the histones.
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Figure 1.3. Illustration of Common Modifications to Histone Proteins.  
Schematic representing the nucleosome core with common post-
translantional histone modifications including: acetyl lysine (acK), methyl 
arginine (meR), methyl lysine (meK), phosphoserine (PS), and 
ubiquitinated lysine (uK).  Post-translational modifications are represented 
by colored shapes (legend in bottom left corner).  Figure reproduced with 
permission.7  
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Deacetylation is performed by the Histone Deacetylase (HDAC) family of proteins 
and results in a closed DNA structure; the cationic lysine tails interact tightly with 
the anionic phosphate backbone of DNA promoting heterochromatin structure 
(Figure 1.4).  Gene repression and altered cell cycle regulation caused by 
overactive HDACs has been linked to the proliferation of cancer, and HDACs 
have been identified as a drug-target for cancer therapy.11  HDAC proteins and 
their inhibitors are the focus of this study. 
 
Figure 1.4. Acetylation/Deacetylation of Lysine Residues. Histone 
acetyl transferase (HAT) enzymes with the co-factor, acetyl-CoA, promote 
acetylation of lysine residues, resulting in a neutral acetyl-lysine and 
euchromatin structure.  Acetylation is a reversible modification, and 
deacetylation is promoted by HDAC proteins.  The anionic lysine residue 
can form a tight electrostatic interaction with the anionic phosphate 
backbone on the DNA, resulting in heterochromatin. 
 
 
 
1.1.3 HDAC Family 
In humans, the HDAC family of proteins is comprised of 18 members, 
divided into four classes by evolutionary similarities.  Class III HDACs are 
comprised of a group of sirtuin proteins that are homologous to the yeast SIR2 
HDACs and rely on a NAD+ mechanism that is distinct from the other HDAC 
proteins; this class of HDACs will not be discussed any further in this dissertation 
O
N
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because they are insensitive to the HDAC inhibitors that are the focus of our 
study.  The class I, II and IV human HDAC proteins share a highly conserved 
metal-dependent active site for efficient acetyl-lysine binding. Class I HDAC 
proteins are comprised of HDAC1, HDAC 2, HDAC 3, HDAC 8 and are 
homologous to yeast protein Rpd3.  The members of class I share a high 
sequence similarity and have a single active site for deacetylation.  These 
proteins are localized to the nucleus due to their role in cell cycle regulation,12-14 
making them prominent targets for cancer treatment. Class II HDACs are 
generally higher in molecular weight than the class I HDACs and are homologous 
to yeast Hda1, which is involved in metabolism.12  This class is further divided 
into two subclasses:  class IIa is comprised of HDAC 4, HDAC 5, HDAC 7, and 
HDAC 9, which, like Class I, have only a single catalytic domain; class IIb 
contains only HDAC 6 and HDAC 10, which both contain a second active site 
(although the second site is only active in HDAC 6).  Unlike Class I HDACs, 
which remain in the nucleus, most Class II HDACs are able to shuttle from the 
nucleus to the cytoplasm where they are involved in metabolic processes.15  
Contrary to Class I HDACs, which are expressed ubiquitously in various cell 
types, Class II HDACs have different expression in various tissues and may be 
involved in differentiation of specific cell types.15  The final class of HDACs, class 
IV, is comprised of only HDAC 11, which resides in the nucleus and has only a 
single active site; HDAC 11 is thought to have diverged from the other HDAC 
proteins early in evolution.  The 11 HDAC enzymes in Classes I, II and IV all 
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have a highly conserved metal dependent active site (section 1.1.4), resulting 
nonspecific binding to most HDAC inhibitors (section 1.2.2).11,16  
 
1.1.4 HDAC Active Site and Biochemical Function 
The catalytic pocket of HDAC family of proteins is highly conserved across 
many species.  There has been limited crystallographic data for human HDAC 
enzymes to offer insight into the structure of the catalytic domain.  The crystal 
structure of class I enzyme, HDAC8, has been solved, but differs significantly 
from other class I enzymes, in that it contains an enlarged binding pocket that 
includes potassium or sodium ions.17  Recently, crystal structures of the catalytic 
domains of enzymes HDAC4 and HDAC7 have been reported, providing insight 
into the class IIa binding sites.18,19  Until recently, when an HDAC2 crystal 
structure was solved,20 the crystal structure of HDAC class I bacterial homolog, 
histone deacetylase-like protein (HDLP), served as a guide to the likely structure 
of class I HDAC binding pocket.21  
HDLP is found in the hyperthermophilic bacterium Aquifex aeolicus, and 
shares 35.2% sequence identity with human HDAC1.  While the native function 
of HDLP is unknown, it has deactelyase function towards histones in vitro at 
7.5% the rate of purified HDAC1-FLAG.21  In addition, the residues around the 
zinc atom in HDLP are completely conserved in human HDAC1, allowing for 
computational homology models of human HDAC1.22  The basic features of the 
HDLP binding pocket are displayed in the crystal structure bound to HDAC 
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inhibitor, trichostatin (TSA) resolved to 2.1 Å (Figure 1.5).21  The active site is 
comprised of a narrow hydrophobic 11Å channel that accommodates the 
aliphatic chain linker of TSA (a common feature of HDAC inhibitors) while the 
hydroxamic acid binds to the catalytic zinc atom at the bottom of the binding 
pocket.  The HDLP binding pocket also has a 14 Å cavity that is believed to 
shuttle in water for catalysis and shuttle out the acetate released during 
deacetylation.22  In addition, the capping group of TSA is shown interacting with 
surface residues at the opening of the binding pocket (will be discussed in the 
context of HDAC inhibitor SAHA in section 2.2.1) (Figure 1.5).  
 
 
 
Figure 1.5. Crystal Structure of TSA in HDLP Binding Pocket.21  
Space filling model showing crystal structure of HDAC inhibitor, TSA, 
bound to HDLP active site resolved to 2.1 Å.  Structural features of HDLP 
active site include an 11 Å channel that binds to aliphatic carbon chains, 
the catalytically important Zn2+ ion at the bottom of the binding pocket, and 
a 14 Å cavity (see text in section 1.1.4 for more detail).  Figure reproduced 
with permission.21  
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A commonly accepted catalytic mechanism for deacetylation of lysine 
residues has been postulated based on the key residues HDLP crystal structure 
resolved to 1.8 Å (Figure 1.6).21  In this mechanism, the ketone of acetyl lysine 
coordinates to the Zn2+ atom, activating the ketone for nucleophilic attack by a 
water atom also coordinated to the Zn2+; the water is activated for deprotonation 
by H131 (H140 in HDAC1) through hydrogen bonding (Figure 1.6 A).  The 
resulting hemiketal is in position to hydrogen bond with neighboring tyrosine 
residue (Y297; homologous to Y303 in human HDAC1) (Figure 1.6 B); this 
tyrosine is substituted by histidine in Class IIa proteins and results in severely 
decreased deacetylation efficiency.18,19,23  The acetate ketone reforms releasing 
lysine, which is protonated by catalytically important histidine residue (H132; 
homologous to H141 in human HDAC1) (Figure 1.6 B and C).  This mechanism 
is generally accepted for the different HDAC homologs, despite different 
biological functions of individual proteins.  Further characterization of the 
functions of different isoforms will be discussed from a genetic approach (section 
1.1.5) and from a chemical approach (section 1.2). 
 
1.1.5 Genetic Characterization of Individual HDAC Function and Cancer 
The characterization of individual isoform functions of human HDAC 
proteins has been largely limited to genetic methods; early genetic profiling of 
HDAC activity using HDAC inhibitors TSA, SAHA, and MS-275 (Figure 1.7) 
indicated that HDACs play a roll in cell cycle progression and cancer.24 
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 A      B 
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Figure 1.6. Proposed Mechanism for Lysine Deacetylation by HDAC 
Proteins.21  Mechanism for deactylation based on crystal structure of 
HDLP protein with catalytically important amino acid residues indicated 
(corresponding human HDAC1 residues indicated in brackets).  A) The 
ketone of acetyl lysine residue coordinates to the Zn2+ atom, activating it 
for nucleophilic attack by a water atom also coordinated to the Zn2+ atom.  
B) The resulting hemiketal forms hydrogen bonds with tyrosine Y297, in 
position to reform of the acetate ketone and release lysine; the lysine is 
protonated by catalytically important histidine residue, H132. C) Lysine 
and acetate ion are released after catalysis.21  Figure reproduced with 
permission.21  
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Unfortunately this study could not pinpoint which HDACs are important in cancer 
due to the lack of isoform selectivity of HDAC inhibitors24 (see section 1.2.2 for 
discussion on HDAC inhibitors).  However, over the past decade genetic 
methods have provided some insight into the function of individual HDAC 
isoforms and revealed which HDACs are likely related to cancer proliferation. 
Early studies into Class I HDAC function included HDAC1 knockout mice, 
which were embryonic lethal, but demonstrated altered cell growth indicating a 
link to cell proliferation.25  Studies of HDAC1, 2 and 3 using small interfering 
ribonucleic acids (siRNA) indicate that these isoforms affect cell morphology and 
cell viability, confirming the role of Class I HDAC proteins in cell cycle 
regulation.26-28  More thorough studies combining siRNA techniques with cDNA 
microarray screening indicate that HDAC1 alone is able to alter expression of 
genes related to cell growth and apoptosis.29  In addition, microarray screening 
has revealed class I HDAC overexpression in some cancer cell lines including 
ovarian (HDAC1-3),30 gastric (HDAC2),31 and lung cancers (HDAC1 and 3).32 
Conversely, the physiological role of class IIa HDAC enzymes has been 
studied using mice knockout experiments implicating both HDAC5 and HDAC 9 
in cardiac development and regulation of cardiac signals;33 similarly, the role of 
HDAC4 in skeletogenesis has been revealed through knockout mice studies.34  
Studies using knockout mice for the final class IIa enzyme, HDAC7, were 
embryonic lethal, but revealed the role of HDAC7 in vascular integretiy.35  Of the 
class II enzymes, only HDAC6 (class IIb) overexpression has been observed 
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through microarray profiling of cancer cells lines (increased in certain breast 
cancers).36 
Recent improvements in genetic technology have allowed for the 
identification of HDACs 1-3 and 6 as important in progression of certain types of 
cancers.  These methods unfortunately suffer from lack of direct temporal control 
that is only possible using small molecule inhibitors.  Conversely, chemical 
genetics have been used as a key strategy towards uncovering the role and 
function of HDAC proteins and will be the central focus of this study (see section 
1.2 below). 
 
1.2  HDAC Inhibitors and Chemical Genetics 
1.2.1 Introduction to Chemical Genetics 
 Over the past two decades, chemical genetics has emerged as an 
important tool to study biological systems through small molecule interactions 
with biomolecules.37  Chemical genetics offers temporal control over protein 
functionality, providing an understanding of short-term effects of protein function 
compared to the long-term effects of eliminating gene products offered by 
classical genetics; chemical genetics can serve as a compliment to traditional 
genetic methods or supplement when genetic methods are not appropriate.37  
The term chemical genetics was first coined by Stuart Schreiber, who was a 
pioneer in the field, exploiting natural products and natural product-like molecules 
to study proteins and their function.37,38 
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1.2.2 HDAC Inhibitors and Chemical Genetics 
In his early work in chemical genetics, Schreiber was interested in 
studying the natural product trapoxin (Figure 1.7), which induced morphological 
changes in mammalian cells.  Through the synthesis of trapoxin linked to a solid 
phase resin (termed K-trap), the Schreiber laboratory was able to isolate a novel 
receptor for trapoxin, which was later termed HDAC1.11,13,24  Trapoxin, like many 
of the known HDAC inhibitors (Figure 1.7), is relatively non-selective towards the 
11 metal-dependent HDAC isoforms.  To date there has been limited 
identification of class selective HDAC inhibitors, and only few HDAC639,40 and 
HDAC8 selective inhibitors are known.41  
Other non-selective HDAC inhibitors (Figure 1.7) have played an important 
role in defining the function of HDAC proteins in cancer.  Specifically, HDAC 
inhibitor trichostatin (TSA) induced G1 phase cell cycle arrest and morphological 
changes in human carcinoma cell lines.42,43  TSA and TSA analogs have also 
stimulated terminal cell differentiation in multiple murine leukemic cell lines.44,45  
The role of HDACs in apoptosis has been further demonstrated in lymphoid, 
colorectal, and neuronal cancer cell lines through TSA-induced activation of 
caspase-3 protease, an effector of cell death.46,47 Similarly, HDAC inhibitors have 
decreased tumor growth in multiple murine models for human cancers including 
mouth, lung, breast, pancreatic, stomach, ovarian, and prostate.48-50 
The specific mechanism of HDAC proteins in cancer has been determined 
from gene profiling studies using HDAC inhibitors, pointing to genes that are 
  
15 
 
Figure 1.7.  Structure of Various HDAC Inhibitors. 
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affected by aberrant HDAC expression in cancer.11,24  HDAC inhibitors induce 
cyclic-dependent kinase inhibitors p21 and p27, which are known to play a role in 
regulated cell cycle progression.  Other genes induced by HDAC inhibitors 
include Fas, FasL, DR-5 and TRAIL death domains, which signal apoptosis.  In 
addition to apoptosis, HDAC inhibitors have been associated with mitotic, 
autophagic and oxidative cell death, further expanding the likely action of HDAC 
inhibitors against cancer cells.11  
The relationship between HDAC proteins, gene regulation and cancer 
proliferation makes them good targets for cancer treatment,11 and several HDAC 
inhibitors are currently in clinical trials for the treatment of cancer.51-53  Two 
HDAC inhibitors have been FDA approved for cancer treatment: suberoyl anilide 
hydroxamic acid (SAHA, Vorinostat, Zolinza) (Figure 1.7),54 and recently FK228 
(romidepsin, Istodax) (Figure 1.7), have been approved for treatment of 
advanced cutaneous T-cell lymphoma.55  
While non-selective HDAC inhibitors have played an essential part in 
elucidating the role of HDAC proteins in cancer and show promise as cancer 
therapeutics, selective HDAC inhibitors have the potential to improve both of 
these avenues.  First, selective inhibitors would allow in vivo studies to determine 
the specific function individual HDAC proteins, which has been difficult using 
traditional cell biology methods (section 1.1.5).  Second, selective HDAC 
inhibitors have the potential to be better drugs with fewer side-effects by targeting 
only the HDACs directly involved in the propagation of specific cancers types.  A 
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substantial limitation towards the identification of selective HDAC inhibitors is the 
lack of screening methods against individual HDAC isoforms. 
 
1.2.3 HDAC Inhibitor Screening 
Finding selective inhibitors for HDAC isoforms requires effective screens 
to probe the binding interaction.  Current methods of screening HDAC inhibitors 
involve a commercially available in vitro fluorescence screening assay from 
Biomol International® using a fluorescently labeled HDAC substrate.56,57  One 
serious limitation of the assay is the reliance on recombinant HDAC expressed in 
baclovirus or mammalian cells, which is intrinsically low yielding, and very costly 
to purchase.  Alternatively, the source of HDAC activity is cellular lysates, which 
contain almost all of the 11 HDACs, making lysates inappropriate for a selectivity 
assay.  In addition, the labeled substrate used in this assay may not indicate the 
true deacetylation activity against native substrates in vivo.  A more desirable 
way to monitor the interaction would be using a high throughput assay that would 
avoid use of recombinant HDACs.  In addition, an in cellulo assay would 
simultaneously screen for cell-permeability.  Alternatively, using antibody 
isolation of individual HDAC isoforms from cellular lysates would also provide 
access to individual HDAC isoforms for selectivity screening. 
The goal of my project is to develop a screening method to evaluate 
HDAC inhibitors against individual HDAC isoforms.  Our strategy involves using a 
bifunctional chemical probe that will bind to HDAC proteins, resulting in a 
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measurable signal.  The chemical probes are termed chemical inducers of 
dimerization (CIDs) for their utility in dimerizing proteins.37  The development of 
CIDs and their utility in chemical genetics will be discussed below (section 1.2.4). 
 
1.2.4 Introduction to Chemical Inducers of Dimerization (CIDs) 
 A common tool used in chemical genetics are bifunctional small 
molecules, used to promote interactions between proteins that would not interact 
under native conditions.  These bifunctional small molecules, or chemical 
inducers of dimerization (CIDs), are small molecules developed to bind two 
proteins simultaneously, causing protein dimerization.58  The utility of CIDs to 
influence biological systems was first introduced by the Schreiber and Crabtree 
labs when they used a homodimer of the small molecule FK506 (termed FK1012) 
to promote oligimerization of FKBP chimeric proteins leading to signal 
transduction in the mammalian cells (Figure 1.8).59  Schreiber took advantage of 
a well-studied signaling pathway that is activated by extracellular aggregation of 
receptors mediated by ligand binding, leading to transphosphorylation of the 
intracellular components of the receptors and resulting signaling cascade.  By 
modifying the receptor system to exclude the extracellular domain and include 
three FKBP proteins on the intracellular domain, the signaling could be restored 
through aggregations mediated by the FK1012 CID (Figure 1.8).  Through this 
work, Schreiber and Crabtree demonstrated that synthetic small molecules could 
  
19 
be used to influence cellular events within mammalian cells, and opened up a 
new avenue of chemical genetics for studying biological pathways. 
 
 
 
Figure 1.8.  Dimerization of Chimeric FKBP12 Through FK1012 CID 
Causes Phosphorylation Signaling Cascade. Chimeric proteins 
containing 3 FKBP12 domains are localized to the cellular membrane 
through myristalation of c-Src amino terminal domain, linked through the ζ 
chain of T cell antigen receptor (TCR) complex.  Presence of the FK1012 
CID causes aggregation of the chimeric proteins, which leads to a 
phosphorylation signaling cascade induced by transphophorylation of the ζ 
chain of TCR complex59.  Abbreviations: phospholipase Cγ1 (PLCγ1); 
diacetyl glycerol (DAG); protein kinase C (PKC); MAP kinase (MAPK); 
nuclear factor of activated T-cells, nuclear and cellular components 
(NFATc,n).  Figure reproduced with permission59. 
  
20 
Since their initial conception, CIDs have been used for a variety of 
applications by promoting non-native biomolecule interactions with both 
homobifunctional and heterobifunctional CIDs.37,58,60  One of the most common 
uses of CIDs has been induction of gene transcription in the three hybrid system, 
which has been developed in mammalian cells,61 yeast,62-70 and bacteria;71 the 
yeast three-hybrid (Y3H) system and its applications will be discussed in detail in 
section 1.3.  CIDs and chemical tools have also been used for biochemical 
studies in vitro and some relevant examples will be discussed in section 1.4.  
Some novel applications of CIDs that were first developed in vitro, and expanded 
to in vivo studies are discussed below. 
 One of the early applications of CIDs, was in mediating protein 
degradation through cellular recruitment to a ubiquitination complex.  
Ubiquitination is a conserved motif for intracellular proteolysis of that is part of 
regulated cellular function.  The Sakamoto group developed several generations 
of CIDs capable of binding to an E3 ubiquitin-protein ligase complex (specifically 
the Skp1-Cullin-F box (SCF) complex) that promotes polyubiquitination of the 
protein IκBα.72-74  Ubiquitination is mediated by IκBα binding to F box protein β-
TrCP, through a 10 amino acid phosphopeptide.  CIDs containing the IκBα 
phosphopeptide and a ligand for a specific protein target were effective in 
causing degradation of the target protein (Figure 1.9); these CIDs were termed 
proteolysis targeting chimeric molecules (Protacs).  This method provides a 
powerful tool for small-molecule induced knockouts, especially in cases where 
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genetic knockouts are unsuccessful.58  The Protac system has been extended to 
other applications notably, targeted proteolysis of cancer-promoting proteins in 
models.74
 
Figure 1.9.  Schematic Representation of the Protac System for 
Targeted Proteolysis.  The Protac-1 CID (teal rhomboid linked to a circle) 
recruits target protein to the E3 Skp1-Cullin-F box (SCF) complex.  In the 
proximity of the SCF complex, the target protein is modified with ubiquitin 
(Ub) and targeted for degradation by the 26S proteasome.  Abbreviation: 
hrt1 (H).  Figure reproduced with permission.58 
 
 
 Recent advances in CID design has led to the development of CIDs that 
can promote an immunogenic response through antibody recruitment targeted to 
a specific cell type.  The Kiessling laboratory has designed a CID capable of 
recruiting anti-Gal antibodies through an α-Gal epitope; the CID was also 
designed to bind to ανβ3 integrin receptors that are upregulated in tumorigenesis, 
through the short arginine-glycine-aspartic acid (RGD) peptide (Figure 1.10).  
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Using this method, the RGD-α-Gal CID was able to bind MCF2 tumor cells and 
recruit antibodies from human serum, demonstrating the potential to exploit the 
immune system by using bifunctional antitumor therapeutics (Figure 1.10).75  
 CIDs have proven to be a powerful tool for chemical genetics and show 
enormous potential for studying any biomolecule with a known high affinity small 
molecule interaction.60  Towards our goal of screening HDAC inhibitors against 
an HDACi-based CID, we look towards the yeast three hybrid system (Section 
1.3) and an in vitro screening method (section 1.4). 
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Figure 1.10.  Targeted Immunogenic Response With RGD-α-Gal CID.  
A) Schematic representation of bifunctional RGD-α-Gal CID binding to 
ανβ3 integrin receptors on target cell and recruiting anti-Gal antibodies. B) 
Flow cytometry histogram demonstrating anti-Gal antibody from human 
serum binding to M21 cells through RGD-α-Gal CID (conjugate 2d in 
figure).  Secondary anti-human antibody labeled with a fluorophore was 
used for detection of binding interaction by flow cytometry.  Figure 
reproduced with permission.75 
  
complex of these a- and b-subunits dictates integrins’ binding
specificity and ultimate biochemical function. The avb3 integrin
mediates the attachment of cells to the extracellular matrix
and has been implicated in tumor-induced angiogenesis,
tumor invasion, and metastasis.[13,14] This integrin is upregulat-
ed on both cancer cells and tumor-associated blood vessels;
however, avb3 is absent or present only at low levels on most
normal tissues.[15] Experiments with arginine-glycine-aspartic
a id (RGD) peptide conjugates suggest that integrins can serve
as cell-surface recepto s for recruiting a ti-Gal antibodies.[16]
Given its location on the cell surface and its role in cancer, we
reasoned that avb3 would serve as an excellent target receptor.
Because they can be readily generated, the most common
integrin l gands u ed are peptides. Linear peptide sequences
containing the RGD motif are known to bind integrins, and
these have been employed as cell-targeting agents.[17] Because
of the low affinity and promiscuity of such linear peptides,
however, their utility for selective cell targeting is limited.ACHTUNGTRENNUNGPeptide derivatives, such as cyclic Arg-Gly-Asp-d-Phe-Lys
[c ACHTUNGTRENNUNG(-RGDfK-) ; 3a, Scheme 1], have been used as tumor-homing
agents due to their selectivity for avb3 over the closely related
aIIbb3 integrin.
[18–20] Although more discriminating than its
linear counterparts, this derivative is also a ligand for the avb5
integrin, a receptor highly expressed on many normal cell
types. For our studies, we required integrin ligands that could
be used for the construction of bifunctional conjugates and
that are selective for the avb3 integrin. Although there are a
few examples,[21–25] nonpeptidic derivatives that satisfy these
criteria are rare. Several uses have been described for peptido-
mimetics that exhibit selectivity in integrin targeting.[26] In one
example, an integrin-binding small molecule was modified so
that it could be conjugated to a variety of antibodies for
tumor targeting.[27–30] This ligand and others equipped with
handles for modification, however, bind the closely relatedACHTUNGTRENNUNGintegrins avb3 and avb5. We set out to expand the toolkit ofACHTUNGTRENNUNGintegrin ligands by generating compounds with the desiredACHTUNGTRENNUNGattributes that are selective for avb3.
Here, we report the modular synthesis of novel functional-
ized avb3 integrin ligands. We generated several bifunctional
conjugates by appending the a-Gal trisaccharide to these li-
gands, thereby highlighting the benefits of our modular syn-
thetic strategy. We also implement an integrin-dependent cell-
adhesion assay to assess the inhibitory potencies of these
compounds. Our results indicate that these peptidomimetics
maintain their binding affinity and possess high specificity for
avb3. Moreover, the modular assembly method that we employ
should facilitate the development of bifunctional conjugates
for a variety of cell-targeting applications.
Results and Discussion
Bifunctional conjugate design
The importance of the avb3 integrin has fueled the discovery
of numerous small-molecule ligands.[31,32] As a starting point
for our studies, we utilized potent avb3 antagonists with well-
characterized integrin-selectivity profiles. We selected two in-
hibitors : the cyclic RGD peptide mimetic 1a and the non-pep-
tidic compound 2a (Scheme 1). Compound 1a inhibits binding
of purified avb3 to an immobilized RGD-containing ligand with
an IC50 value of 20 nm ; it preferentially binds avb3 over the pla-
telet integrin aIIbb3 with 1000-fold greater activity.
[33,34] Com-
Figure 1. Schematic description of anti-Gal antibody recruitment to the
target cell surface by a bifunctional ligand. One portion of the conjugate is
designed to selectively bind to cells displaying the avb3 integrin, while the
other displays the a-Gal carbohydrate epitope, which can interact with anti-
Gal antibodies.
Scheme 1. Target functionalized avb3 integrin ligands (1b, 1c, 2c, 2d, 3c) and the parent compounds (1a, 2b, 3a) from which they are derived.
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Ligands that Target Integrin-Displaying Cells
In addition to high affinity, our targeting strategy requires
that the bifunctional ligands possess high selectivity for the
target avb3 integrin. To assay for specificity over a key related
integrin, avb5, we utilized MCF7 human breast carcinoma cells,
which are known to display avb5. Vitronectin, the natural pro-
tein ligand for this receptor,[62] was substituted for fibrinogen
in our fluorescence-based cell-binding assay. Under these con-
ditions, we measured a significantly higher IC50 value of 7.8!
5.7 mm for conjugate 2d, which represents more than a 4000-
fold decrease in potency. This value suggests that compound
2d is even more selective for avb3 integrin than the compound
(2a) upon which it is based. These data suggest that conju-
gates based on our the potent inhibitor 2d will exhibit excel-
lent cell-targeting selectivity.
Antibody-binding assay
For our synthetic conjugates to function as designed, t ey
must bind to avb3-displaying cells and interact simultaneously
with anti-Gal antibodies. To evaluate whether they can act in
this capacity, we incubated an avb3-positive cell line, M21
human melanoma cells, with 10 nm of compound 2d and
human serum; the latter serves as a source of anti-Gal IgG. To
test for binding of anti-Gal, washed cells were treated with a
fluorescein-labeled anti-human IgG secondary antibody an
subsequently analyzed by flow cytometry. In the absence of
2d, the cells displayed no anti-Gal binding; however, cells
treated with 2d exhibited a significant increase in the fluores-
cence signal (Figure 3). These results indicate that bifunctional
ligand 2d maintains its ability to interact with anti-Gal antibod-
ies when bound to the surface of avb3-positive cells. Because
both the integrin binding domain and the anti-Gal epitope can
function simultaneously, our results bode well for using these
or related bifunctional ligands as novel tumor-targeting
agents.
Conclusions
In summary, we have successfully developed a modular route
to bifunctional conjugates that target cells displaying the avb3
integrin. In devising integrin ligands with the appropriate at-
tributes, we designed and synthesized two avb3-binding small
molecules with excellent potencies. In addition, the selectivity
of compound 2d for avb3 over related integrins indicates that
it is a valuable new addition to the limited set of functionalized
non-peptidic ligands that bind this receptor.
The sites for modification integrated into our avb3 integrin li-
gands and the dimethyl squarate coupling chemistry that we
h ve employed can be exploited for a variety of purposes. F r
instance, the handles we have installed can be used immo-
bilize the integrin ligands, thereby creating surfaces for avb3-
positive cell adhesion or growth.[26,66] Alternatively, these han-
dles can serve as points of attachment to tumor imaging
ag nts. Finally, ur functionalized integrin li ands can be used
to append protein or small-molecule toxins to create novel an-
titumor agents.
Experimental Section
General : All materials were obtained from commercial suppliers
and used as provided unless otherwise noted. Reaction solvents
were purified by distillation by using standard protocols. Tetrahy-
drofuran (THF), diethyl ether, toluene, and benzene were distilled
from sodium metal and benzophenone under an argon atmos-
phere. Triethylamine and dichloromethane were distilled from cal-
cium hydride. Methanol was distilled from magnesium. Dimethyl-
formamide (DMF) was rendered amine-free by treatment with
Dowex 50WX8–200 cation-exchange resin (H+ form, 1 gL"1). Di-ACHTUNGTRENNUNGmethylsulfoxide (DMSO) was stored over 3 ! molecular sieves. All
moisture- and air-sensitive reactions were carried out in flame-
dried glassware under an atmosphere of nitrogen. Liquid reagents
were introduced by oven-dried glass syringes. To monitor the
progress of reactions, thin-layer chromatography (TLC) was per-
formed with Merck (Darmstadt) silica gel 60 F254 precoated plates
by eluting with the solvents indicated. Analyte visualization was ac-
complished by busing a multiband UV lamp and charring with one
of the following stains: p-anisaldehyde, ninhydrin, potassium per-
manganate, or phosphomolybdic acid. Flash chromatography (FC)
was performed on Scientific Adsorbents Incorporated silica gel
(32–63 mm, 60 ! pore size) by using distilled reagent-grade hex-
anes and ACS-grade ethyl acetate or methanol and chloroform. 1H
and 13C NMR spectra were recorded on Bruker AC-300 or Varian
Inova-500 spectrometers, and chemical shifts are reported relative
to tetramethylsilane (TMS) or residual solvent peaks in parts per
Table 1. Inhibition constants (IC50 values) of compounds 1a–c, 2a–d, and
3a–c determined in an assay assessing the binding of avb3-positive
WM115 cells to immobilized fibrinogen.
Compound IC50 [nm] Compound IC50 [nm]
1a 61!30 1b 68!100
1c 930!600 2a 8.1!2
2b 0.55!0.2 2c 1.3!0.4
2d 1.8!0.7 3a 24!6
3b >5000 3c 47!50
Figure 3. Representative flow cytometry histogram illustrating anti-Gal anti-
body binding to M21 cells. M21 tumor cells were treated with bifunctional
conjugate 2d and human s rum, a source of anti-Gal IgG. Antibody bi ding
was detected by flow cytometry and a fluorophore-labeled secondary anti-
human antibody.
74 www.chembiochem.org " 2007 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2007, 8, 68 – 82
L. Kiessling et al.
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1.3 Yeast Three-Hybrid (Y3H) System 
1.3.1 Introduction to the Yeast Three-Hybrid System  
 In order to screen small molecule inhibitors of HDAC, the interaction 
between HDAC and HDAC inhibitor must produce a detectable signal.  One 
method of monitoring small molecule-protein interactions in vivo is by using the 
yeast three-hybrid system.62  Yeast have been used as a powerful tool in 
chemical genetics due to their well-studied genome that shares high genetic 
conservation with humans, and their ease of growth and manipulation.60  The 
Y3H is an extension of the yeast two-hybrid system, which relies on direct 
protein-protein interaction in the absence of small molecules.76  In the Y3H 
system (Figure 1.11) a CID (or “bait”) promotes interaction between two hybrid 
proteins, promoting gene transcription and a detectable signal.  One of the hybrid 
proteins has a DNA binding domain (DBD) and a ligand binding domain to bind 
the CID.  The DBD anchors the other two hybrid components to the DNA allowing 
for transcription, and has been termed the “hook”.62  The other hybrid protein  
(termed the “fish”) has a ligand binding domain for the other part of the CID, and 
an activation domain (AD) that recruits the transcriptional machinery thereby 
activating expression of the target gene. When both hybrid proteins are 
expressed in yeast containing a reporter plasmid, incubation with the CID causes 
dimerization, promoting gene transcription and a resulting signal (Figure 1.11).62  
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Figure 1.11. The Yeast Three Hybrid System.  The three-hybrid system 
consists of two hybrid proteins and a CID designed to bind to the two 
hybrid proteins.  In the presence of CID, the components of the Y3H 
interact.  The “hook” consists of a ligand-binding protein linked to a DNA-
binding domain that interacts with an operator on the DNA containing the 
reporter gene, anchoring the components to the DNA.  The “fish” 
component consists of a second ligand binding protein linked to an 
activation domain, which will induce gene expression when in proximity to 
the reporter gene.  The CID is the “bait” that binds to both of the ligand 
binding domains and brings all the components of the system together, 
resulting in gene expression and an observable signal.62 
 
 
 
 The Y3H was first introduced by Licitra and Lui in 1996, who synthesized a 
CID composed of the hormone dexamethasone (DEX), and the small molecule 
FK506.62  DEX was used as a binding partner for rat glucorticoid receptor (rGR) 
linked to the DBD LexA; fusion proteins of the GAL4 activation domain (B42) 
were screened from a Jurkat cDNA library (Figure 1.12).  The reporter plasmid 
used in this system contained lexA operators directing the transcription of the 
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lacZ gene encoding for β-galactosidase (β-Gal) enzyme.  A qualitative agar 
plate-based assay was used with the β-Gal substrate, 5-bromo-4-chloro-3-indolyl 
β-D-galactoside (X-gal), which is cleaved to a visibly blue product in the presence 
of β-Gal enzyme. Using this method, Licitra and Lui confirmed two variants of the 
FKBP12 protein as binding partners for the FK506-DEX CID.62  Screening using 
the Y3H system was achieved in a fraction of the time it would have taken using 
purely biochemical methods.62  Significantly, the DEX-FK506 interaction with the 
FKBP12-B42 hybrid proteins could be disrupted in the presence of 10-fold 
excess of FK506, indicating that the Y3H may be useful for competitive inhibitor 
screening.62  This report set a precedent for the utility of screening small 
molecule-protein interactions using the Y3H system. 
 
 
 
Figure 1.12. Licitra and Luiʼs Y3H.62  Hybrid protein LexA-rGR binds to 
the LexA operator of the LacZ reporter plasmid.  In the presence of the 
DEX-FK506 CID, hybrid protein of FKBP12-B42 is recruited to the DNA, 
inducing transcription of β-galactosidase enzyme. 
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1.4.1 Cornishʼs Dexamethazone-Methotrexate Y3H 
The most well-characterized Y3H to date was developed in the Cornish 
laboratory in 2000.63 In this report, they took advantage of the strong interaction 
between the small molecule methotrexate (MTX) and the protein dihydrofolate 
reductase (DHFR) to provide a strong anchor between the “hook” and the “bait”  
in the system (Figure 1.13).  This interaction is a suitable anchor for the Y3H 
system because the MTX-DHFR interaction has been well characterized,77,78 and 
displays picomolar affinity;63 the interaction between MTX and DHFR has since 
been exploited in several three-hybrid systems.68,79,80  Cornish used a CID 
comprised of MTX linked to DEX to recruit the rGR fused B42 AD.63  The first 
report of this system used a similar agar-plate based screening methods for 
identifying active Y3H systems, but also included a quantitative method for 
screening Y3H systems using the β-Gal substrate ο-nitrophenyl-β-D-galactoside 
(ONPG) in liquid culture; the ο-nitrophenol cleavage product can be measured 
spectrophotometrically at 420 nm.81  The liquid based assay is advantageous for 
high throughput inhibitor screening because it reduces the amount of inhibitor 
required by screening in small volumes, and allows quantitative assessment of 
CID binding.  Cornish also optimized her Y3H to incorporate the cDNA encoding 
for LexA-DHFR hybrid protein within the yeast chromosome, which showed more 
stable results in the Y3H.63,66,67  Importantly, as in the DEX-FK506 system, the 
MTX-DEX CID could be out-competed in the presence of 10 fold excess of MTX, 
further evidence that the Y3H may be useful for inhibitor screening.57,60,67 
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Figure 1.13. Cornish's Y3H.  Hybrid protein LexA-DHFR binds to the 
LexA operator of the LacZ reporter plasmid.  In the presence of the DEX-
MTX CID, hybrid protein of rGR-B42 is recruited to the DNA, inducing 
transcription of β-galactosidase enzyme.63,66,67 
 
 
 
1.4.2 Petersonʼs Estrone-Biotin Y3H 
In 2004, Peterson introduced a Y3H based on a CID comprised of an 
estrone oxime linked to biotin. This CID promoted the dimerization of a LexA 
fused to estrogen receptor (ER) protein and a hybrid Steptavidin(SA)-B42 protein 
to activate gene transcription of β-galactosidase (Figure 1.14).64  Similar to a β-
estradiol-biotin CID-based system that he had introduced earlier,65 the estrone-
biotin CID offered a synthetically accessible method for preparing CIDs that can 
interact with high affinity in the Y3H system.64  Peterson was also able to disrupt 
the interaction between estrone-biotin CID and the SA-B42 hybrid protein in the 
presence of 10-fold excess of biotin, giving further evidence that competitive 
inhibitors can effectively disrupt the Y3H.  
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Figure 1.14. Petersonʼs Y3H.  Hybrid protein LexA-ERβ binds to the 
LexA operator of the LacZ reporter plasmid.  In the presence of the 
estrone-biotin CID, hybrid protein of SA-B42 is recruited to the DNA, 
inducing transcription of β-galactosidase enzyme.64 
 
1.4.3 Competitive Inhibitor Screening Using a Y3H System 
There is ample evidence suggesting that the Y3H may be an effective tool 
for screening small molecule-protein interactions.62-66,82  While the utility has thus 
far been limited to screening cDNA libraries encoding for hybrid proteins linked to 
an activation domain, the precedent for disrupting the Y3H by a competitive 
inhibitor has been set by many groups.62-64,82  In addition, a similar system in 
mammalian cells has been used for screening competitive kinase inhibitors.79  
We proposed that competitive HDAC inhibitors could be screened in a similar 
manner by disrupting the binding of an HDACi-based CID to a HDAC hybrid 
protein, causing a loss of signal.  In this way, the presence of a small-molecule-
protein interaction could be easily detected and monitored.  Design of an HDAC-
based Y3H will be discussed in Chapter 2. 
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1.5 In vitro Selectivity Screening 
Chemical genetics have also been used to study biological systems in 
vitro when cellular approaches are not appropriate.  Similar to our proposed Y3H 
competitive inhibitor screen, CID displacement been used to assess kinase 
inhibitor selectivity against various kinase proteins in vitro.83,84  Ambit 
Biosciences has developed kinase inhibitor-based CIDs which are linked to biotin 
for isolation from cellular lysates with magnetic streptavidin coated beads (Figure 
1.15).  For this application, biotin-containing kinase inhibitor CIDs have been 
used to assay competitive inhibitors against individual kinases displayed on T-7 
bateriophage in E. coli lysates.83,84  Using this method, kinase targets could be 
detected when bound to the CID, and amplified using reverse transcriptase 
polymerase chain reaction (rtPCR).  Importantly, the assay was able to determine 
in vitro Kds for competitive inhibitors against individual kinase proteins.83,84  
Development of a biotin-based HDAC inhibitor CID for in vitro inhibitor screening 
will be discussed further in Chapter 3.  
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 Figure 1.15.  In Vitro Kinase Inhibitor Selectivity Screen.  Streptavidin 
beads (represented by the semi-circle on the right of each diagram) were 
coated with biotin-kinase inhibitor CID (biotin as part of the bead with 
kinase inhibitor represented by the red hexagons).  The coated beads 
were used to isolate T-7 bacteriophages (large blue hexagons) displaying 
individual kinase proteins (left panel).  In the presence of competitive 
kinase inhibitors (green hexagons, middle panel), the isolation of T-7 
bacteriophages displaying individual kinase proteins is disrupted; non-
competitive inhibitors fail to disrupt the kinase-bead interaction (right 
panel).  Figure reproduced with permission.83  
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While this specific type of screening method has not been used for 
assessing HDAC inhibitors, in vitro approaches to studying HDAC proteins with 
HDACi-based probes has been successful in several studies.  As discussed in 
section 1.2.2, the initial isolation of human HDAC1 was achieved using a small a 
covalent HDAC inhibitor (trapoxin) displayed on a solid resin.13  This year, a large 
study was published using resin-based non-covalent HDAC inhibitors (SAHA and 
govinostat) to isolate megadalton HDAC protein complexes, followed by mass 
spectrometric analysis.5  Significantly, the bead-based SAHA and govinostat 
probe interactions with HDAC proteins was disrupted in the presence of pre-
incubated competitive HDAC inhibitors (Figure 1.16).5  Using this method, 
several HDAC inhibitors were screened for binding affinity towards class I and 
class IIb HDAC proteins and their corresponding cellular complexes.  From the 
mass spectrometric analysis of the proteins isolated by these probes both in the 
absence of competitive inhibitors, and in addition of varying concentrations of 
competitive HDAC inhibitors, IC50 values were extrapolated (Figure 1.16).5  Using 
this method the known HDAC 1-3 selective inhibitor romidepsin85 (FK228; Figure 
1.16) was confirmed to have greater affinity towards HDACs 1-3 compared to 
HDACs 6, 8 and 10, demonstrating the utility of in vitro screening to identify 
HDAC selective inhibitors.5  In this study, HDAC isoforms were not isolated 
individually, but the megadalton complex components were verified by 
quantitative co-immunoprecipitation.5  This study provides precedence for our 
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proposed in vitro competitive inhibitor screen that will be discussed in detail in 
Chapter 3.   
 
 
 
Figure 1.16.  Competitive HDAC Inhibitor Disruption of HDAC Protein 
Isolation.  HDAC inhibitors SAHA, BML210, Tacedinaline and 
Romidepsin (FK228) IC50 determinations were extrapolated through 
competitive disruption of SAHA-based and govinostat-based probes to 
HDACs 1-3, 6, 8 and 10.  Figure reproduced with permission.5    
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CHAPTER 2 
DEVELOPMENT OF A HDAC-BASED YEAST THREE HYBRID SYSTEM 
 
2.1 Development of a Y3H for HDAC Inhibitor Screening 
2.1.1 Competitive HDAC Inhibitor Screening 
Class I HDAC enzymes play an important role in gene regulation, and 
inhibitors of this family of proteins have been identified as targets for cancer 
therapy.  Many of the known HDAC inhibitors are non-selective towards the 11 
metal-dependent HDACs and current methods are limited in screening inhibitors 
for selectivity against individual HDAC isoforms.  A high-throughput screening 
method has the potential to significantly improve current methods of identifying 
selective HDAC inhibitors (HDACi).  
 Towards the goal of developing a competitive HDACi screening method, 
we sought to develop Y3H systems (section 1.3) centered around hybrid HDAC 
proteins interacting with HDACi-based CIDs (specifically SAHA-based CIDs; for 
discussion and synthesis see section 2.2).  We worked on two systems based on 
Petersonʼs Y3H system64 (section 1.3.3):  the first was based on a SAHA-Estrone 
CID (section 2.1.2; synthesis sections 2.2.2-2.2.3); the second was centered on a 
SAHA-Biotin CID (section 2.1.3; synthesis section 2.2.4).  The final Y3H that we 
sought to develop was centered on a SAHA-MTX CID (section 2.1.4, synthesis 
section 2.2.4) based on Cornishʼs Y3H system63,77,78 (section 1.3.2). 
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 Following the previous work done in the Cornish63,77,78 and Peterson64 
laboratories, we developed a general strategy for an HDAC-dependent Y3H 
(Figure 2.1).  The components of our Y3H include a hybrid protein consisting of 
bacterial DNA binding domain, LexA, linked to a protein that will bind to a SAHA-
based CID.  The SAHA-based CID will also interact with a hybrid HDAC protein 
fused the transcriptional activation domain, B42.The three hybrid components will 
interact with a reporter plasmid through LexA operators bringing B42 into 
proximity of the lacZ gene inducing expression of the β-galactosidase enzyme 
(Figure 2.1 A). 
 The goal of our HDAC-based Y3H system is to screen competitive HDAC 
inhibitors by blocking binding interactions between hybrid HDAC proteins and 
SAHA-based CIDs, thereby preventing gene expression and signal induction 
(Figure 2.1 B).  A major advantage to this method would be that the HDAC 
isoforms could be screened individually against HDACi and allow for assessment 
of selectivity.  In Figure 2.1 B, the competitive HDACi would disrupt the 
interaction between the CID (“bait”) and the hybrid protein containing the 
transcriptional activation domain (“fish”).  Our SAHA-estrone and SAHA-MTX 
Y3H systems use this strategy, while in our SAHA-biotin system the HDAC is 
fused to the DNA-binding domain and competitive inhibitors would disrupt the 
hook-bait interaction (section 2.1.3).  The positive control used in the Y3H assay 
consisted on one hybrid protein of LexA and B42 that simultaneously binds the 
DNA through LexA operators and activates transcription of the lacZ gene (Figure 
  
36 
 
 
Figure 2.1. General Scheme of HDAC-Dependent Y3H For 
Competitive Inhibitor Screening.  A) In the presence of SAHA-based 
CID, the components of the Y3H will interact causing gene transcription of 
β-galactosidase and a measurable signal.  B) In the presence of a 
competitive HDACi the interaction between HDAC-B42 hybrid protein and 
SAHA-based CID is disrupted, failing to induce gene expression.  C) 
Positive control for the Y3H relies on a fusion protein of LexA and B42, 
which induces gene expression in the presence of reporter plasmid.   
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2.1 C).   The specific components of the different systems will be discussed in 
greater detail below (sections 2.1.2-2.1.4). 
 
2.1.2 SAHA-Estrone Based Y3H 
The first HDAC-dependent Y3H assay was inspired by Petersonʼs Y3H 
system64 (section 1.3.3) using a SAHA-estrone CID (for structure and synthesis 
see section 2.2.2-2.2.3), in lieu of an estrone-biotin CID, to recruit an HDAC-B42 
hybrid protein (Figure 2.2).  Our Y3H were performed in Saccharomyces 
cerevisiae strain FY250 (MATα, ura3-52, his3Δ200, leu2Δ1, trp1Δ63), a 
generous gift from Blake Peterson.64,65  The plasmids used in the Y3H systems 
were under control of a galactose 1 promoter (Pgal1), meaning that genes for 
hybrid proteins and reporter enzymes were only induced in the presence of 
galatose-containing media; yeast were grown in the absence of galactose prior to 
the assay.  The reporter plasmid, pSH18-34 (a gift from Peterson) was used, 
which has 8 lexA operators directing transcription of lacZ gene encoding for β-
galactosidase enzyme under the control of a GAL1 promoter.  Other important 
features of this plasmid include URA3 yeast selection and ampicillin resistance 
(ampR) in bacteria (2μ origin).  The second yeast expression plasmid gifted by 
Peterson64,65 was pAM423-LexA ERβ (HIS3, 2μ, Pgal1, ampR), encoding for a 
fusion protein of LexA and estrogen receptor β (ERβ) (Figure 2.3) followed by 
and ADH termination sequence (AdhT).  The pSA1 T7-SA yeast expression 
plasmid, also donated by the Peterson laboratory,65 was used to clone DNA 
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encoding for HDAC1-B42 and Rpd3-B42 fusion proteins into EcoRI/XhoI 
restriction sites using homologous recombination (for complete details see 
experimental section 2.7).  Important features of these HDAC-B42 encoding 
plasmids include TRP1 yeast selection, AMP resistance in bacteria, a GAL1 
promoter and Adh termination domain (see section 2.7 and Figure 2.9).  The 
positive control for this system was a one-hybrid LexA-B42 fusion protein from 
pSH17-4 yeast expression plasmid (Origene, HIS3, Pgal1, 2μ, ampR). With all the 
DNA components for the Y3H in hand, a synthetic strategy for the SAHA-estrone 
CID was developed (section 2.2.3-2.2.4). 
 
 
 
Figure 2.2.  Pflum Lab Y3H based on SAHA-Estrone CID. Hybrid 
protein LexA-βER binds to the LexA operator of the LacZ reporter plasmid.  
In the presence of the SAHA-estrone CID, hybrid protein of HDAC-B42 is 
recruited to the DNA, inducing transcription of β-galactosidase enzyme.  
HDAC in this figure could represent yeast HDAC, Rpd3; or human 
HDAC1.  
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2.1.3 SAHA-Biotin Based Y3H 
The Y3H system based on a SAHA-biotin CID (Figure 2.3; for structure 
and synthesis see section 2.2.4) was also inspired by Petersonʼs Y3H system 
(section 1.3.3) using yeast strains and plasmids that he generously gifted our 
lab64,65 (see section 2.1.2 for details).  As in the SAHA-estrone based Y3H, the 
pSH18-34 reporter plasmid was used to mediate expression of β-glactosidase 
under the influence of the three hybrid components (section 2.1.2).  In addition 
the yeast expression plasmid, pSA1 T7-SA (TRP1, 2μ, Pgal1, AdhT ampR), 
encoding for the streptavidin-B42 fusion protein was used to bind the biotin 
portion of the SAHA-biotin CID.  HDAC1-LexA fusion protein was expressed from 
yeast plasmid pNLexA-VP16-HDAC1 (cloned by Mary Kay H. Pflum from 
commercially available pNLexA to include human HDAC1-VP16 at the N-terminal 
of LexA into EcoRI and NotI restriction sites, unpublished; HIS3, 2μ, Pgal1, AdhT 
ampR).  Important features of this plasmid include HIS3 yeast selection, and amp 
resistance in bacteria.  The final component of the Y3H was a SAHA-biotin CID, 
which was synthesized using a solid-phase strategy (section 2.2.4). 
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Figure 2.3.  Pflum Lab Y3H based on SAHA-Biotin CID.  Hybrid protein 
LexA-HDAC1 binds to the LexA operator of the LacZ reporter plasmid.  In 
the presence of the SAHA-estrone CID, hybrid protein of SA-B42 is 
recruited to the DNA, inducing transcription of β-galactosidase enzyme.  
 
 
 
2.1.4 SAHA-MTX Based Y3H 
The final HDAC-dependent Y3H assay was designed centered around a 
SAHA-MTX CID (for structure and synthesis see section 2.2.5).  This system was 
based on Cornishʼs Y3H system (section 1.3.2) using Saccharomyces cerevisiae 
strain, V760Y (MATα trp1 ura3 6lexAop-LEU2 ade4::Pgal1-LexA-eDHFR(HIS3) 
GAL+), that she generously gifted our lab.63,67  The V760Y strain was cloned from 
strain EGY48 to interrupt the ADE4 chromosomal gene with cDNA encoding for a 
fusion of LexA protein linked to dihydrofolate reductase enzyme from E. coli 
(eDHFR) flanked by a GAL1 promoter and ADH termination domain.  This yeast 
strain was used with reporter plasmid pMW112, also a gift from the Cornish 
laboratory,63,67 which has 8 lexA operators directing transcription of lacZ gene 
encoding for β-galactosidase enzyme under the control of a GAL1 promoter; 
other important features of this plasmid include URA3 yeast selection, and 
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kanamycin resistance (kanR) in bacteria.  This Y3H system was used with a 
SAHA-MTX CID in separate experiments to recruit either an HDAC1-B42 or an 
Rpd3-B42 fusion protein (pSA1 HDAC1-B42; pSA1 Rpd3-B42; for description 
see section 2.1.2 and experimental section 2.7).  The positive control for this 
system was a fusion of LexA-B42 fused to the N-terminal of catalytically inactive 
mutant HDAC1(H141A) from plasmid p424 HDAC1(H141A)-LexA (Sujith 
Weerasinghe unpublished, TRP1, ampR, GPD promoter, CYC1 terminator).86  
The design and synthesis of the SAHA-based CIDs for the Y3H systems are 
discussed in section 2.2 below; specifics of the SAHA-MTX CID synthesis is 
discussed in section 2.2.5.  
 
 
 
Figure 2.4.  Pflum Lab Y3H based on SAHA-MTX CID. Hybrid protein 
LexA-DHFR binds to the LexA operator of the LacZ reporter plasmid.  In 
the presence of the SAHA-MTX CID, hybrid protein of HDAC-B42 is 
recruited to the DNA, inducing transcription of β-galactosidase enzyme.  
HDAC in this figure could represent yeast HDAC, Rpd3; or human 
HDAC1. 
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2.2 SAHA-Based CIDs 
2.2.1 Design of SAHA-Based CIDs 
To create the HDAC-dependent Y3H systems, we next designed HDACi 
CIDs.  Our HDACi-based CIDs incorporate the small molecule SAHA (Figures 1.7 
and 2.2), which has a synthetically accessible structure and is known to inhibit all 
of the HDAC isoforms relatively nonselectively.16,87  Based on the crystal 
structure of SAHA binding to a bacterial HDAC homolog HDLP (see section 1.1.4 
for discussion of active site), we reasoned that the optimal place to derivatize 
SAHA would be on the aromatic ring, which is located in the solvent exposed 
region when SAHA binds to the active site of HDAC proteins (Figure 2.5).21,88  
Structure activity relationship (SAR) studies of SAHA indicate that substituents 
along the linker chain of SAHA near the hydroxamic acid severely decrease 
binding affinity towards HDAC proteins,89 while modifications towards the solvent 
exposed region (Pflum and Bieliauskas unpublished data), and to the aromatic 
ring of HDAC inhibitors can actually increase potency.16,51,90  For our SAHA-
based CIDs, the aromatic ring will be functionalized to display either an amine or 
carboxylic acid that will be connected through a linker and to the second small 
molecule of the CID.  
For the synthesis of SAHA-based CIDs, several different methods were 
explored to develop a facile synthesis that could be amended to accommodate 
different small molecules attached to SAHA through a linker.  A general strategy 
was desired where either an amine or carboxylic acid would be displayed on the
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Figure 2.5 Crystal Structure of SAHA in the HDLP Active Site.  A) 
Structure of SAHA.  B) Space filling model of crystal structure of SAHA in 
the HDLP binding pocket. Zinc atom is colored purple; oxygen is red; 
nitrogen is blue; carbon is yellow.  Reproduced with permission.88  
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aromatic ring of SAHA, which is positioned in the solvent exposed region as 
SAHA binds to the active site of HDAC proteins.  Our initial plan for the synthesis 
of the SAHA-based CIDs was to employ traditional solution phase synthesis by 
successive amide bond coupling reactions (section 2.2.2); this method was used 
towards the development of a SAHA-estrone Y3H (section 2.1.2, synthesis 
section 2.2.3).  A solid-phase synthesis was then established for the 
development of the SAHA-biotin Y3H (section 2.1.3 synthesis section 2.2.4) and 
for the SAHA-MTX Y3H (section 2.1.4, synthesis section 2.2.5). 
 
2.2.2 Exploratory Solution-Phase SAHA-Based CID Synthesis 
 The synthesis of the SAHA fragment of the CID in solution phase was 
inspired by a previously reported synthesis of SAHA, in which suberic acid (2) 
was converted into the cyclic anhydride 3.  In this report, the anilide was installed 
by ring opening with aniline, followed by installation of the hydroxamic acid to 
afford SAHA (1) (Scheme 2.1).52  
 
Scheme 2.1.  Previous SAHA Synthesis.52 
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Following the previous method,52 suberic acid 2 was converted into 
suberic anhydride 3 in the presence of acetic anhydride (Scheme 2.2).  Initially, 
aniline derivatives 5a-d with nucleophilic moieties at the para and meta positions 
were used to open anhydride 3, but all resulted in products that were highly 
insoluble in organic solvents and therefore not conducive to further 
transformations (Scheme 2.2). 
 
Scheme 2.2. Exploratory SAHA Analog Synthesis 
 
  
As an alternative to the synthetic strategy from the published SAHA 
synthesis (Scheme 2.1), the hydroxamate was installed first by opening suberic 
anhydride 3 with O-benzyl protected hydroxylamine to provide O-benzyl 
protected hydroxamate 8 (Scheme 2.3). The benzyl protection was chosen 
because of the ease of deprotection in the presence of palladium on carbon and 
hydrogen gas, which would avoid the difficult purification of the hydroxamic acid 
by column chromatography.  Soluble hydroxamate 8 was then coupled to aniline 
derivative 5a in the presence of carbodiimide (CDI) and triethylamine (TEA), but 
again yielded an insoluble SAHA derivative, 9 (Scheme 2.3).  To circumvent 
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solubility issues associated with the SAHA derivatives, aniline derivatives with 
carbon linkers between the aromatic ring of SAHA and the added functional 
group were used for future syntheses.  As an alternative method, hydroxamate 8 
was preactivated in the presence of DIPCDI and N-hydroxy succinimide (NHS), 
and then coupled to unprotected 4-aminophenylacetic acid (10) in the presence 
of TEA to afford SAHA fragment 11 containing a free carboxylic acid for future 
derivatization.  With a viable strategy for a solution-phase synthesis of SAHA-
based CIDs, a strategy for the synthesis of a SAHA-estrone CID was developed 
(section 2.2.3). 
 
Scheme 2.3. Solution-Phase Synthesis of SAHA for CID Synthesis 
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2.2.3 Solution-Phase Synthesis of SAHA-Estrone CID 
The solution-phase synthesis was designed initially for the creation of a 
SAHA-estrone CID inspired by Petersonʼs estrone-biotin CID synthesis (Scheme 
2.4) from the Y3H system discussed in section 1.3.3.64  Petersonʼs laboratory 
constructed the estrone-biotin CID 18 by first converting commercially available 
estrone 12 to oxime 14 in the presence of carboxymethoxylamine 
hemihydrochloride 13, followed by amide coupling reactions to incorporate the 
N,Nʼ-dimethyl-1,6-hexanediamine linker 15 and activated biotin fragment 17 with 
a 6-amino caproic acid linker.64 
 
Scheme 2.4. Synthesis of Petersonʼs Estrone-Biotin CID.64  
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Based on the previous syntheses of SAHA and estrone, we devised a 
retrosynthesis to create a SAHA-estrone CID 19 (Scheme 2.5).  In this scheme, 
the SAHA fragment 20, with a 6-amino caproic acid linker, would be coupled to 
estrone fragment 16, linked through N,Nʼ-dimethyl-1,6-hexanediamine.  The 
linker 21 was to be coupled to SAHA fragment 11, which would be synthesized 
(following the method in section 2.2.2) from suberic acid (2), O-benzyl 
hydroxylamine (7), and aniline derivative 10.  Estrone fragment 16 would come 
from estrone 12, carboxymethoxylamine hemihydrochloride 13 and diamine linker 
15 following Petersonʼs protocol (Scheme 2.4).64 
This strategy to create the SAHA-Estrone CID (Scheme 2.6) was based 
on the method reported by Peterson.64  First, SAHA fragment 11 was pre-
activated in the presence of DIPCDI and NHS, then coupled to unprotected 6-
aminocaproic acid (21) in the presence of TEA to afford SAHA fragment 20 
(Scheme 2.6).  This SAHA fragment was very difficult to purify, and only limited 
1H NMR characterization was obtained; this material was used to attempt the 
SAHA-estrone synthesis (below).  Following Petersonʼs Protocol, estrone 12 was 
converted to oxime 14 in the presence of hydroxylamine 13, and then in a two- 
step one pot synthesis,64 amine linker 15 was couple to the oxime followed by 20 
(Scheme 2.7).  Unfortunately, this strategy resulted in a mixture of products that 
was difficult to purify from amine and carboxylic acid components.  An alternative 
solid-phase synthesis was developed towards the synthesis of SAHA-Biotin CIDs 
(section 2.2.3) and used to develop a SAHA-MTX CID (section 2.2.4).  
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Scheme 2.5. Retrosynthesis of SAHA-Estrone CID. 
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Scheme 2.6. Synthesis of SAHA Fragment (20). 
 
 
 
Scheme 2.7. Attempted Synthesis of SAHA-Estrone CID (19). 
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amide coupling and deprotections used to construct the SAHA-based CIDs.  This 
method has been used to create hydroxamic acids using hydroxylamine Wang 
resin,91-93 including in the synthesis of HDACi-based probes published by the 
Cravatt laboratory shortly after we began using this method.94  
A retrosynthesis (Scheme 2.8) using the hydroxylamine Wang resin was 
devised for the creation of SAHA-biotin CID A (22).  In this scheme, biotin 23 and 
polyethylene glycol linker 24 would be added to SAHA based bead 25 through 
amide coupling reactions.  SAHA bead 25, functionalized with an amine for 
coupling reactions, would come from hydroxylamine Wang resin 27, suberic 
anhydride 3, and Boc-protected 4-amino benzylamine 26.  
Using this method, the aniline derivative 28 was first selectively Boc 
protected in high yield, then used to open suberic anhydride to afford derivative 
29 (Scheme 2.9).  This suberoyl anilide derivative 29 was then coupled to 
hydroxylamine Wang resin 27 to give bead-based SAHA derivative 25, which 
was then Boc deprotected in the presence of 20% trifluroacetic acid (TFA) in 
dichloromethane (DCM).  Polyethylene glycol linker 24 was then added to the 
beads, in the presence of diisopropylethylamine (DIPEA) and O-(Benzotriazol-1-
yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), followed by Fmoc 
deprotection in the presence of 20% piperidine in DMF to afford SAHA fragment 
30.  Finally, biotin (23) was added under similar coupling conditions, followed by 
cleavage from the resin using TFA in DCM (1:1)93,95 to give SAHA-biotin CID A 
(22) (Scheme 2.9); anhydrous conditions were used during resin cleavage to 
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avoid hydrolysis of the hydroxamic acid to the corresponding carboxylic acid.91  
The HPLC purification of this compound revealed a mixture of products, and only 
a trace amount of 22 was isolated (no yield calculated, Appendix A.13.1).  In 
addition, HPLC reinjection of this compound revealed degradation to several 
different peaks.    
 
Scheme 2.8.  Retrosynthesis of SAHA-Biotin CID A (22). 
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Scheme 2.9.  Synthesis of SAHA-Biotin CID A (22). 
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This first version of the SAHA-biotin CID A was used in NeutrAvidin pullout 
experiments described in Chapter 3 (section 3.2.1, Figure 3.2).  Although the 
initial experiments were successful, further experiments were limited due to poor 
stability of the CID, and HPLC reinjection revealed further decomposition of the 
purified CID (Appendix A.13.2).  A decomposition pathway was proposed to 
describe the low stability of the SAHA-biotin CID A (Figure 2.6).  The acidic 
conditions used to cleave the SAHA-based CIDs from the Wang resin allowed for 
a stable amide leaving group, which in combination with resonance from the 
anilide into the aromatic ring, provided a likely route for SAHA-biotin CID A (22) 
decomposition (Figure 2.6). 
 
 
Figure 2.6. Proposed Decomposition Pathway of SAHA-Biotin CID A 
(22).  In the presence of H+, the anilide amine electron pair could resonate 
through the aromatic ring causing elimination of the stable amide leaving 
group and resulting in cleavage of SAHA-biotin CID A (22). 
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To overcome this instability, while maintaining a similar synthetic route, 4-
aminophenylethylamine (31) was used in the place of 4-(amino)benzyl amine 
(28) to determine if an additional methylene between the amine and the aromatic 
ring would eliminate the decomposition pathway.  Initially, the SAHA-biotin CID B 
(36) was constructed following the same method (Scheme 2.10) as the synthesis 
in the original SAHA-biotin CID A (22) in Scheme 2.9.  Using the alternative 
aniline derivative, SAHA was constructed on the bead first by Boc protecting 4-
aminophenylethylamine 31 in high yield, followed by opening suberic anhydride 3 
to produce aniline 33, which was then coupled to the hydroxylamine Wang resin 
27 in the presence of DIPEA and TBTU (Scheme 2.10).  Once the Boc group 
was deprotected in the presence of 20% TFA in DCM, polyethylene glycol linker 
24 was then coupled to the beads, followed by Fmoc deprotection in the 
presence of 20% piperidine in DMF.  Finally, biotin (23) was added under similar 
coupling conditions before the CID was cleaved from the bead in the presence of 
TFA and DCM (1:1) to afford SAHA-biotin CID B (36) in 2.8% overall yield over 6 
steps.  
The new version of the SAHA-biotin CID (36) showed an increase in the 
ratio of product to side products present in the HPLC after cleavage from the 
Wang resin (Appendix A.14.1).  However, the use of the Boc protection on aniline 
derivative 32 required a 20% TFA solution for deprotection on the resin, while the 
conditions used to cleave the hydroxylamine from the resin were 50% TFA over a 
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90 minute period.  The use of the Boc protection, and the cleavage in TFA 
potentially lowered the yield of the SAHA-biotin CID B (36). 
 
Scheme 2.10. Initial Bead-Based Synthesis of SAHA-Biotin CID B (36). 
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To avoid possible complications associated with using the Boc protecting 
group with the Wang resin, an alternate and simplified retrosynthesis for SAHA 
bead (34) was devised using an Fmoc protection strategy (Scheme 2.11).  In this 
scheme, SAHA bead (34) would come from Fmoc protected aniline derivative 37, 
suberic acid monomethyl ester 38 and hydroxylamine Wang resin 27 connected 
through amide bonds. 
 
Scheme 2.11. Retrosynthesis of Bead-Based SAHA Using Fmoc Protection. 
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to selectively protect the primary amine and avoid side-reactions with the 
aromatic amine.   
 
Scheme 2.12. Fmoc Protection of 2-(4-aminophenyl)ethylamine (31) 
 
 
For the bead synthesis, first suberic acid monomethyl ester 38 was added 
to hydroxylamine Wang resin 27 in the presence of DIPEA and TBTU to 
construct the hydroxamate on the resin (Scheme 2.13).  The methyl ester was 
then hydrolyzed in saturated lithium hydroxide (LiOH) mixed with THF in a 
biphasic solution (1:2) for 8 hours.96  The free carboxylic acid of bead 40 was 
then coupled to Fmoc protected derivative 37 in the presence of DIPEA and 
TBTU, followed by Fmoc deprotection in the presence of 20% piperidine in DMF 
to give SAHA fragment 23.  The PEG linker and biotin were then added following 
the same method used in Scheme 2.10, followed by cleavage from the bead to 
give identical SAHA-biotin CID B (36) in 7.7% yield over 8 steps (Scheme 2.13).  
The low yield may be due to Fmoc deprotection of aniline 37 during the coupling 
to hydroxylamine Wang resin 27; perhaps the yield may be improved if less 
DIPEA is used during this step under more dilute coupling conditions.  This 
SAHA-biotin CID B (36) was used in the Y3H (results section 2.3) and towards 
development of an in vitro assay (Chapter 3). 
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Scheme 2.13. Optimized Synthesis of SAHA-Biotin CID B (36) 
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2.2.5 Synthesis of SAHA-MTX 
Several solid phase synthetic routes towards SAHA-based CID syntheses 
were explored in the development of the SAHA-biotin CIDs discussed in section 
2.2.4.  For the synthesis of SAHA-MTX the most direct route was used.  A 
retrosynthetic strategy was devised (Scheme 2.14) where MTX fragment 42 
would be added to the SAHA-based resin in the final step through amide 
coupling; the MTX fragment 42 would come from aromatic alcohol 44 and N-
methyl p-amino benzoic acid (N-methyl PABA) 45.  The glutamic acid portion of 
MTX would be added to the SAHA-based resin 43 through an amide bond to the 
side-chain carboxylic acid of glutamate by employing an Fmoc protection on the 
amine and tBu protection and the C-terminal carboxylic acid (Fmoc-Glu-OtBu 46) 
(Scheme 2.14).  For the synthesis of SAHA-MTX, SAHA bead 45 would be 
synthesized using the most direct method following the synthesis outlined in 
Scheme 2.13. 
With an efficient bead-based synthesis of SAHA-based CIDs in hand, the 
MTX fragment 42 was generated following a previous protocol.97  First, 2,4-
Diamino-6-(hydroxymethyl)pteridine hydrochloride 44 was converted in the 
presence of triphenyl phosphine dibromide to aryl bromide 47, which then 
underwent SN2 reaction with N-methyl PABA 45 to give MTX fragment 42 
(Scheme 2.15).  Prior to coupling MTX fragment 42 to the bead, Fmoc-Glu-OtBu 
46 was coupled to bead 35 and Fmoc deprotected (Scheme 2.9).  Once MTX 
fragment 42 was linked to SAHA using standard coupling conditions, the CID was 
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Scheme 2.14. Retrosynthesis of SAHA-MTX CID. 
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cleaved from the resin in 50% TFA/DCM, simultaneously removing the tBu 
protection. The SAHA-MTX CID 41 was purified by HPLC in 5.2% yield for 
application to the Y3H system (results sections 2.3). 
 
Scheme 2.15. Synthesis of MTX fragment of SAHA-MTX. 
 
   
 
 
Scheme 2.16. Synthesis of SAHA-MTX CID. 
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2.3 Three Hybrid Screen Results and Discussion 
2.3.1 SAHA-Biotin Y3H  
With all the plasmid components and SAHA-biotin CID B (36) in hand, the 
yeast three hybrid assay (section 2.2.3) was performed (Figure 2.7).  Negative 
controls were performed with yeast containing only the reporter plasmid pSH18-
34 (lanes1 and 4) and positive controls were performed with yeast containing 
reporter plasmid and LexA-B42 expression plasmid pSH17-4 (lanes 3 and 6).  
The assay was performed in both the absence (lanes 1-3) and presence (lanes 
4-6) of SAHA-biotin CID B (36).  There was strong activation of β-galactosidase 
activity in the positive control of more than 100 fold over the negative control.  
There was no activation of β-galactosidase in Y3H system containing all of the 
plasmid components (Reporter, HDAC1-LexA and SA-B42) in either the absence 
or presence of 36.  The failure for the SAHA-biotin CID to induce gene 
expression is likely due to the yeast cell impermeability of SAHA, demonstrated 
independently by Sujith Weerasinghe.98 In a similar one-hybrid screen, Sujith was 
able to slightly increase the SAHA cell permeability through cell wall degradation 
with the lytic enzyme zymolyase.  Our Y3H was also performed in the presence 
of zymolyase enzyme (Figure 2.7, red bars), but did not have an effect on β-
galactosidase activity in the Y3H in the presence of SAHA-biotin CID B (lane 5).  
While biotin has been used successfully in Petersonʼs yeast systems,64,65,99 these 
results suggest that SAHA is not appropriate for studies in yeast due to cell 
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impermeability.  Similar results were obtained in the SAHA-MTX Y3H (section 
2.3.2). 
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Figure 2.7.  Results of the SAHA-Biotin Y3H. Relative β-Galactosidase 
activity from ONPG cleavage expressed as (OD420)/[OD600*volume of 
culture (0.25 mL)*time (min)]; control lane 1 (-) zymolyase set as 1. 
Reporter is pSH18-34; SA-B42 from plasmid pSA1 T7SAB42; HDAC1-Lex 
from plasmid pN LexA-HDAC1-VP16; LexA-B42 from plasmid pSH17-4; 
assay performed in S. cervisiae strain FY250, for detail see section 
2.2.3.64,65,99  Results are the average of two independent trials.  
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2.3.2 SAHA-MTX Y3H  
With a viable synthesis of SAHA-MTX CID (41) (section 2.2.5), yeast 
expression plasmids for HDAC1-B42 and Rpd3-B42 were created (section 2.7).   
With all of the components in hand the SAHA-MTX Y3H assay was performed 
(Figure 2.8).  Negative controls were performed with yeast containing only the 
reporter plasmid pMW112 with LexA-DHFR expression encoded into the 
chromosomal DNA67 (lanes1 and 5) and positive controls were performed with 
yeast containing reporter plasmid and LexA-B42 (lanes 4 and 8).  The assay was 
performed in both the absence (lanes 1-4) and presence (lanes 5-8) of SAHA-
MTX CID (41).  There was strong activation of β-galactosidase activity in the 
positive control of 25-45 fold over the negative control and no activation of β-
galactosidase in Y3H system containing all of the plasmid components (Reporter, 
HDAC1-LexA and SA-B42) in either the absence or presence of 41.  Similar to 
the SAHA-biotin Y3H (section 2.3.1), zymolyase did not increase the activation of 
β-galactosidase in the presence of SAHA-MTX with either human HDAC1-B42 
AD (lane 7) or with the yeast Rpd-B42 AD (lane 6).  MTX had been used in many 
Y3H systems,63,66-68,80 giving further evidence that SAHA likely obstructs cell 
permeability of the CID, and is not appropriate for the development of a yeast 
three-hybrid system.  In addition, MTX has recently been revealed to inhibit 
HDAC proteins100, further complicating the development of this assay.   
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Figure 2.8. Results of the SAHA-Biotin Y3H Relative β-galactosidase 
activity from ONPG cleavage expressed as (OD420)/[OD600*volume of 
culture (0.25 mL)*time (min)]; control lane 1 (-) zymolyase set to 1. 
Reporter is pMW112; LexA-DHFR integrated into yeast chromosome of S. 
cerevisiae strain V760Y; Rpd3-B42 from plasmid pSA1 Rpd3-B42; 
HDAC1-B42 from plasmid pSA1 HDAC1-B42; LexA-B42 from plasmid 
p424 LexA-HDAC1(H141A)-B42; for detailed description see section 
2.2.4.  Results are the average of two independent trials.  
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2.4 Solution Phase Synthetic Methods 
2.4.1 General Chemicals and Characterization 
 Unless noted otherwise, solvents were purchased from Fisher Scientific, 
Mallinckrodt Chemicals or EMD Chemicals and used without further purification; 
Tetrahydrofuran (THF) was freshly distilled before use from sodium 
benzophenone ketyl immediately prior to use; DriSolve® dimethyl formamide 
(DMF) was purchased from EMD.  Reagents were generally purchased from 
Fisher Scientific, Acros Organics, or Sigma Aldrich.  Flash chromatography was 
carried out using 60 Å, 230-400 mesh silica gel.  NMR spectra were taken on 
either a Varian Unity 300 MHz, Varian L900 400 MHz, or a Varian 500 MHz.  IR 
spectra were taken on a Bruker Tensor 27.  HRMS spectra were taken on either 
a Waters LCT Premier XE ESI-LC–MS TOF or a Waters GCT EI-TOF.  Spectra 
are included in Appendix A. 
 
2.4.2 Solution-Phase Syntheses 
 
 
Suberic Anhydride (3).  Acetic anhydride (10.0 mL, 99.3 mmol) was added to a 
flame-dried flask containing suberic acid 2 (5.00 g, 28.7 mmol).   The solution 
was heated to dissolve the suberic acid, and refluxed for an hour.   The solvent 
was then removed under reduced pressure, and the resulting solid was 
OO O
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recrystallized from acetonitrile to afford 3 as a fine white powder (4.3 g, 96%).  1H 
NMR (400 MHz, CDCl3): δ 2.46 (t, 4 H), 1.66 (m, 4 H), 1.39 (m, 4 H); 13C NMR 
(100 MHz, CDCl3): δ 169.8, 35.5, 28.5, 24.0; IR: 2934, 2912, 2872, 2853, 1813, 
1742.36, 1702, 1473, 1415, 1381, 1333, 1218, 1195, 1047, 1010, 910, 795, 726, 
684 cm-1; HRMS (ESI-LC–MS, m/z); calculated [M+H]+ for C8H13O3 157.0865; 
found: 157.0870. 
 
 
8-(benzyloxyamino)-8-oxooctanoic acid (8). O-benzyl hydroxylamine 
hydrochloride (1.508g, 9.45mmol) was added to a separatory funnel containing a 
solution of sodium carbonate (601 mg, 5.67 mmol) in water (10 mL).  The neutral 
compound was extracted using ethyl ether (3x10 mL) and dried with magnesium 
sulfate.  The solution was concentrated in vacuo, and diluted with THF (10 mL).  
A solution of suberic anhydride 3 (984 mg, 6.3mmol) in THF (10 mL) was added 
dropwise, and the solution was stirred overnight.  The product was purified by 
flash chromatography (10:9:1, EtOAc/Hex/AcOH) to afford 8 as a white solid 
(1.065g, 61% yield).  1H NMR (500 MHz, CD2Cl2): δ 7.35 (m, 5H), 4.87 (s, 2 H), 
2.28 (m, 2H), 2.01 (m, 2H), 1.58 (m, 4H), 1.28 (m, 4H); 13C NMR (125 MHz, 
CD2Cl2): δ 179.1, 129.5, 128.9, 78.4, 34.2, 33.3, 28.9, 27.3, 24.7; IR: 3227, 3033, 
2937, 2863, 1694, 1657, 1500, 1255, 1194, 737, 698 cm-1; HRMS (ESI-LC–MS, 
m/z); calculated [M+H]+ for C15H22NO4 280.1549; found: 280.1540. 
O
H
N O
O
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2-(4-(8-(benzyloxyamino)-8-oxooctanamido)phenyl)acetic acid (11). 
Compound 8 (1.832g, 6.56 mmol) was stirred overnight with DIPCDI (1.1 mL, 
7.03 mmol), and N-hydroxyl succinimide (906 mg, 7.87mmol) in 50 mL of 
dichloromethane.  Activation of the acid was judged by TLC (9:1 DCM/MeOH, Rf 
= 0.75).  4-aminophenylacetic acid 10 (2.975g, 19.68mmol) and triethylamine 
(7.3 mL, 52.51 mmol) were added to the reaction and stirred for 2 hours.  The 
reaction was quenched with 1 M aqueous HCl (10 mL) causing an off-white 
precipitate to form.  The solid was collected and the supernatant was transferred 
to a separatory funnel and extracted with EtOAc (3x 30 mL) and dried with 
magnesium sulfate.  The precipitate was added to the organic extract, and was 
dried loaded onto silica gel and purified by flash chromatography (17:2:1, 
DCM/acetone/AcOH) to afford 11 as a pale yellow solid (1.631 g, 60%).  1H NMR 
(300 MHz, DMSO): δ 12.25 (bs, 1 H), 10.92 (s, 1H), 9.81 (s, 1 H), 7.49 (d, 2H), 
7.35 (m, 5H), 7.13 (d, 2H), 4.78 (s, 2 H), 3.45 (s, 2H), 2.25 (t, 2 H), 1.92 (t, 2 H), 
1.51 (m, 4 H), 1.24 (m, 4H); 13C NMR (75 MHz, DMSO): δ 173.9, 171.7, 170.1, 
138.6, 136.8, 130.2, 129.4, 129.0. 128.9, 119.8, 77.5, 37.0, 32.9, 29.1, 28.9, 
25.7, 25.5; IR: 3277, 3240, 3034, 3007, 2933, 2852, 1656, 1602, 1556, 1413, 
1252, 1175, 1021, 981, 814, 732, 697 cm-1; MS (ESI-LC–MS, m/z); calculated 
[M+H]+ for C23H29N2O5 413.2, found: 413.2 (M+H)+; calculated [M+Na]+ for 
C23H28N2O5Na 435.2, found: 435.2; [M+K]+ for C23H28N2O5K 451.2, found: 451.2; 
O
H
N O
O
N
H
HO
O
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[2M+H]+ for C46H57N4O10 825.4, found: 825.5; [2M+Na]+ for C46H56N4O10Na 
847.3, found: 847.4; [2M+K]+ for C46H56N4O10K 863.4, found: 863.4. 
 
 
SAHA fragment (20). Compound 11 (297 mg, 0.72 mmol) was stirred overnight 
with DIPCDI (0.13 mL, 0.792 mmol), and N-hydroxyl succinimide (NHS) (99 mg, 
0.864mmol) in 10 mL of dimethylformamide.  6-Aminohexanoic acid 21 (285 mg, 
2.16mmol) and triethylamine (0.8 mL, 5.76mmol) were added to the reaction and 
stirred for 2 hours.  The reaction was quenched with 1 M aqueous HCl (10 mL) 
causing a white precipitate to form.  The solid was collected and the supernatant 
was transferred to a separatory funnel and extracted with EtOAc (3x 30 mL).  The 
organic layer was then washed 3x20 mL water and 1x20 mL brine to remove any 
residual DMF.  The precipitate was added to the organic extract, and was dried 
loaded onto silica gel and purified by flash chromatography (88:10:2, 
DCM/EtOH/TEA) to afford 20 as an off-white solid, and was used without further 
purification.  See Appendix A.4 for crude 1H NMR (400 MHz, DMSO) spectra. 
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 Estrone Oxime (14). Estrone 12 (251 mg, 0.93 mmol) was dissolved in pyridine 
and stirred overnight with carboxymethoxylamine hemihydrochloride 13 (285 mg, 
2.6mmol).  Once the reaction was complete as judged by TLC analysis (Rf = 0.3, 
CH2Cl2 / CH3OH, 4:1) the reaction mixture was poured into 30 mL of 10% 
hydrochloric acid cooled on ice.  The product was extracted with EtOAc (3 x 30 
mL) and the organic layers were combined and dried with MgSO4.  The reaction 
mixture was dry-loaded onto silica gel for purification by column chromatography 
(DCM/MeOH, 4:1) to give a white powder (310 mg, 97% yield). 1H NMR (400 
MHz, CD3OD): δ 7.44 (s, 1H), 7.06 (d, 1H), 6.57 (d, 1H), 6.51 (s, 1H), 4.37 (s, 
2H), 4.01 (bs, 1H), 2.78 (t, 2H), 2.55 (t, 2H), 2.29 (d, 1H), 2.17 (t, 1H), 1.97 (d, 
1H), 1.88 (m, 2H), 1.44 (m, 6H), 0.89 (s, 3H); 13C NMR (100 MHz, CD3OD): δ 
171.4, 155.7, 137.7, 130.7, 126.7, 115.6, 113.5, 70.6, 53.0, 44.3, 44.1, 38.5, 
34.6, 29.7, 27.6, 26.5, 23.2, 17.8; IR: 3362, 3326, 3037, 2968, 2932, 2868, 1686, 
1663, 1598, 1522, 1453, 1324, 1287, 1249, 1170, 1085, 1064, 912, 872, 818, 
710 cm-1; HRMS (ESI-LC–MS, m/z); calculated [M] for C20H25NO4 343.1784, 
found: 343.1788. 
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tert-butyl 4-aminobenzylcarbamate (26). Di-tert-butoxycarbonate (5.6 mL, 26.2 
mmol) was added slowly to a stirred solution of 4-(amino)benzyl amine  28 (2.8 
mL, 24.7 mmol) in THF (20 mL) cooled to 0 °C, and stirred at room temperature 
for 2 hours.  The solution was then purified by flash chromatography (3:2 ethyl 
ether/petroleum ether) to afford 26 as a yellow solid (5.216g, 95.0%).  1H NMR 
(400 MHz, CDCl3): δ 7.06 (d, 2H), 6.62 (d, 2H), 4.78 (bs, 1H), 4.18 (d, 2H), 3.56 
(bs, 2H), 1.43 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 156.1, 145.7, 129.1, 115.5, 
79.8, 44.6, 28.7; IR: 3454, 3369, 3223, 3033, 3012, 3000, 2980, 2970, 2876, 
1688, 1625, 1518, 1458, 1364, 1247, 1163, 1120, 1027, 931, 865, 822, 787 cm-1; 
HRMS (ESI-LC–MS, m/z); calculated [M] for C12H18N2O2 222.1368;  found: 
222.1374. 
 
 
8-((4-(((tert-butoxycarbonyl)amino)methyl)phenyl)amino)-8-oxooctanoic 
acid (29). A solution of suberic anhydride 3 (6 mmol, 937 mg) in dichloromethane 
(6 mL) was added dropwise to a stirred solution of 26 (6 mmol, 1.334 g) in 
dichloromethane (6 mL) cooled to 0 °C, and stirred at room temperature for one 
hour.  The solvent was then evaporated under reduced pressure, and the 
resulting solid was recrystallized from acetonitrile to give 29 as an off-white 
BocHN
NH2
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powder (1.588 g, 70%). 1H NMR (400 MHz, DMSO): δ 11.97 (s, COOH), 9.80 (s, 
1H), 7.50, (d, 2H), 7.30 (t, NH, 1H), 6.13 (d, 2H), 4.04 (d, 2H), 2.27 (t, 2H), 2.18 
(m, 2H), 1.52 (m, 4H), 1.37 (s, 9H), 1.28 (m, 4H); 13C NMR (100 MHz, DMSO): δ 
175.2, 171.8, 156.4, 138.6, 135.3, 128.0, 119.6, 78.8, 43.7, 37.0, 34.3, 28.9, 
25.9, 25.0; IR: 3354, 3321, 3186, 3119, 3040, 2981, 2941, 2852, 1686, 1658, 
1597, 1519, 1411, 1367, 1339, 1285, 1253, 1171, 1045, 1028, 968, 929, 865, 
837, 784, 724, 691 cm-1; MS (ESI m/z) calculated [M+H]+ for C20H31N2O5 379.22, 
found: 379.28; calculated [M+Li]+ for C20H30N2O5Li 385.23, found: 385.32; 
calculated [M+Na]+ for C20H30N2O5Na 401.21, found: 401.26; calculated [M+K]+ 
for C20H30N2O5K 417.18,  found: 417.22. 
 
 
tert-butyl 4-aminophenethylcarbamate (32).  Di-tert-butoxycarbonate (3.3 mL, 
15.4 mmol) was added slowly to a stirred solution of 4-aminophenylethylamine 31 
(2.00 g, 14.7 mmol) in THF (100 mL) cooled to 0 °C.  The mixture was stirred 
overnight at room temperature.  Solid yellow tert-butyl 4-
aminophenethylcarbamate 32 was obtained (3.284 g, 95%) after column 
purification (7:1, petroleum ether/ethyl ether).  1H NMR (400 MHz, DMSO): δ 6.80 
(d, 2H), 6.45 (d, 2H), 4.82 (s, 2H, NH2), 3.34 (t, NH, 1H), 3.00 (q, 2H), 2.47 (t, 
2H), 1.35 (s, 9H); 13C NMR (100 MHz, DMSO): δ 156.2, 147.4, 129.6, 126.9, 
114.6, 78.1, 42.8, 36.2, 29.0; IR: 3362, 3330, 3005, 2980, 2941, 2871, 1711, 
1687, 1664, 1520, 1411, 1392, 1366, 1250, 1225, 1171, 1042, 999, 965, 837, 
NH2
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802, 692 cm-1; MS (ESI m/z) calculated [M+H]+ for C13H21N2O2 237.2, found: 
237.4; calculated [M+Li]+ for C13H20N2O2Li 243.2, found: 243.4; calculated 
[M+Na]+ for C13H20N2O2Na 259.1, found: 259.4; calculated [M+K]+ for 
C13H20N2O2K 275.1, found: 275.3. 
 
 
8-((4-(2-((tert-butoxycarbonyl)amino)ethyl)phenyl)amino)-8-oxooctanoic 
acid (33).  A solution of suberic anhydride 3 (453 mg, 2.9 mmol) in 
dichloromethane (15 mL) was added dropwise to a solution of tert-butyl 4-
aminophenethylcarbamate 32 (685 mg, 2.9 mmol) in dichloromethane (15 mL) 
and stirred overnight.  The reaction mixture was then dry-loaded onto silica gel 
and purified by flash chromatography starting with 1% triethylamine in 
dichloromethane with increasing polarity to 1% triethylamine with 4% methanol in 
dichloromethane to 10% methanol then 15% methanol until all the product had 
eluted from the column to give 33 as an off-white solid (489 mg, 43.0%).  1H NMR 
(400 MHz, DMSO): δ 9.79 (s, 1H), 7.47 (d, 2H), 7.07 (d, 2H), 6.84 (t, 1H), 3.07 
(q, 2H), 2.60 (t, 2H), 2.53 (t, 2H), 2.17 (t, 2H), 1.55 (t, 2H), 1.48 (t, 2H), 1.35 (s, 
9H), 1.27 (m, 4H); 13C NMR (100 MHz, DMSO): δ 175.3, 171.7, 138.1, 134.5, 
129.4, 119.7, 42.3, 40.2, 38.4, 37.0, 28.9, 25.7, 25.2; IR: 3362, 3329, 3188, 
3115, 3035, 2983, 2941, 2870, 1815, 1744, 1683, 1597, 1515, 1468, 1449, 1411, 
1367, 1327, 1295, 1248, 1170, 1136, 1041, 998, 967, 871, 838, 801, 691 cm-1;  
N
H
BocHN O
OH
O
  
75 
MS (ESI m/z) calculated [M+H]+ for C21H33N2O5 393.2389 found: 393.2388; 
calculated [M+Na]+ for C21H32N2O5Na 415.2209, found: 415.2212; calculated 
[M+K]+ for C21H32N2O5K 431.1948, found: 431.1929.  
 
 
(9H-fluoren-9-yl)methyl 4-aminophenethylcarbamate (37). N-(9-
Fluorenylmethoxycarbonyloxy)succinimide (4.402 g, 13.05 mmol) was added in 
one portion to a solution of 2-(4-aminophenyl)ethylamine 31 (1.615 g, 11.86 
mmol)  in dioxane (120mL) cooled to 15 °C.  The solution was stirred at room 
temperature overnight.  Water (120 mL) was then added to the reaction and the 
solution was neutralized with saturated sodium bicarbonate; the resulting 
precipitate was removed by filtration. The aqueous solution was extracted with 
dichloromethane (3 x 100 mL).  The organic layer was dried with magnesium 
sulfate, concentrated and purified by flash chromatography (2% acetone in 
dichloromethane) to give 37 as a pale yellow solid (2.675 g, 63%). The final 
compound was not exposed to heat while dissolved in column solvent to avoid 
self-deprotection of the Fmoc group, and the final compound was rinsed with 
ethyl ether to remove any deprotected material. 1H NMR (400 MHz, DMSO): δ 
7.91 (s, 2H), 7.71 (d, 2H), 7.44 (t, 2H), 7.35 (m, 3H), 6.87 (d, 2H), 4.89 (s, 2H), 
4.32 (d, 2H), 4.24 (d, 1H), 3.16 (q, 2H), 2.56 (t, 2H); 13C NMR (125 MHz, DMSO): 
δ 156.7, 147.5, 144.6, 141.4, 129.7, 128.2, 127.7, 126.9, 120.8, 114.7, 65.9, 
47.4, 43.1, 35.4; IR: 3449, 3367, 3318, 3063, 3038, 3021, 2971, 2938, 2871, 
NH2
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2856, 1685, 1621, 1685, 1621, 1583, 1547, 1519, 1466, 1410, 1283, 1256, 1196, 
1144, 1100, 1083, 1030, 1006, 936.33, 823, 758, 741, 682 cm-1; MS (ESI m/z) 
calculated [M+H]+ for C23H23N2O2 359.2, found: 359.3, calculated [M+Li]+ for 
C23H22N2O2Li 365.2, found: 365.3; calculated [M+Na]+ for C23H22N2O2Na 381.2, 
found: 381.3; calculated [M+K]+ for C23H22N2O2K 397.1, found: 397.3. 
 
  
6-(bromomethyl)pteridine-2,4-diamine (47).  Triphenylphosphine dibromide 
(49.676 g, 118 mmol) was stirred in a flask containing N,Nʼ-dimethylacetamide 
(DMA) and cooled to near 10 °C. Alcohol 44 (8.178 g, 35.76 mmol) was added in 
one portion, and the solution was stirred at room temperature for 3 to 3.5 hours.  
The solution was then treated with 2.4 mL of ethanol, added dropwise, and 
stirred for 15 minutes.  Benzene (380 mL) was then added to the solution, stirred 
for 30 minutes, and left at 4 °C overnight during which time a semi-solid formed. 
The supernatant was then decanted from the flask, and 195 mL of glacial acetic 
acid (heated to 100 °C) was added, stirred to dissolve, and filtered while hot.  The 
solution was left at room temperature for 4 hours, after which the beige solid that 
had formed was collected and washed thoroughly with ethyl ether.  The crude 
product was then recrystallized from hot isopropanol to give 47 as a brown 
crystalline solid (5.539 g, 39.1%).97 1H NMR (400 MHz, DMSO): δ 9.29 (d, 2 H), 
9.03 (s, 1H), 8.76 (bs, 1 H), 7.62 (bs, 1H), 4.91 (d, 2H); 13C NMR (100 MHz, 
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DMSO): δ 163.2, 156.5, 151.3, 149.9, 146.3, 123.2, 49.0, 31.5; IR: 3556, 3342, 
3126, 2930, 2863, 2785, 2679, 1662, 1555, 1504, 1414, 1363, 1175, 1019, 990, 
737, 674 cm-1; MS (ESI-LC–MS, m/z); calculated [M+H]+ for C7H8BrN6 255.0, 
found: 255.2; calculated [M+Li]+ for C7H7BrN6Li 261.0, found: 261.3; calculated 
[M+Na]+ for C7H7BrN6Na 277.0, found: 277.2; [M+K]+ for C7H7BrN6K 293.0, 
found: 293.2. 
 
 
MTX fragment (42).  Bromide 47 (481mg, 1.06 mmol) and N-methyl-4-
aminobenzoic acid 45 (248 mg, 1.65 mmol) were combined in DMA (1.2 mL).  
The mixture was heated to reflux at 55°C for 4 hours.  The reaction was cooled to 
room temperature and 18 mL of water was added to the reaction.  The resulting 
precipitate was then collected by filtration, and dissolved in 15 mL of 0.08 M 
sodium hydroxide.  The solution was filtered through celite and then acidified to 
pH 6.5 with dilute hydrochloric acid to give yellow solid 42 (569 mg, 53.7%).97 1H 
NMR (400 MHz, DMSO): δ 8.21 (s, 1 H), 8.02 (bs, 1H), 7.77 (bs, 1H), 7.72 (d, 
2H), 6.98 (s, 2H), 6.81 (d, 2H), 4.79 (s, 2 H), 3.21 (s, 3H); 13C NMR (100 MHz, 
DMSO): δ 168.1, 163.5, 162.1, 153.8, 152.7, 149.8, 147.8, 132.8, 122.4, 118.3, 
112.1, 55.2; IR: 3465, 3361, 3326, 3195, 2941, 1605, 1561, 1524, 1448, 1368, 
1248, 1186, 1112, 1001, 949, 920, 828, 776, 701 cm-1; MS (ESI-LC–MS, m/z); 
N
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calculated [M+H]+ for C15H15N7O2 326.14, found: 326.21; calculated [M+Na]+ for 
C15H14N7O2Na 348.12, found: 348.23; [M+K]+ for C15H14N7O2K 364.42, found: 
364.18. 
 
2.5 Solid-Phase Synthetic Methods 
2.5.1 General Methods and Characterization 
 Tetrahydrofuran (THF, EMD Chemicals) was freshly distilled from sodium 
benzophenone ketyl immediately prior to use, or purified by Vacuum 
Atmospheres Company solvent purifier; DriSolve® dimethyl formamide (DMF) 
was purchased from EMD Chemicals.  Hydroxylamine Wang resin was 
purchased from Novabiochem (catalog number 01-64-0454; typically 1.9 mmol/g 
resin); 2-[2-(Fmoc-amino)ethoxy]ethoxy}acetic acid linker was purchased from 
Peptides International (catalog number FXX-5521-PI);  Fmoc-Glu-OtBu was 
purchased from Novabiochem (catalog number 04-12-1075). 
 All bead reactions were performed in a glass vessel with a fritted disc and a 
stopcock to ensure that solvent and reactants could be removed easily and the 
resin could be washed effectively.  Hydroxylamine Wang resin was soaked in 
THF (5 bead volumes) for 45-60 minutes to allow bead swelling prior to 
synthesis.  Due to the non-polar nature of the polystyrene-based Wang resin, 
swelling is maximized in non-polar solvents like THF:  most of the reagents that 
were used in the coupling reactions are soluble in polar solvents like DMF, and 
so a 1:1 mixture of the two solvents was used for all the coupling steps.  Coupling 
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reactions were performed in the presence of 3 equivalents of reactant, 3 
equivalents of TBTU and 6 equivalents of DIPEA.  The resin was agitated during 
the reactions using a Burrel Model 75 wrist action shaker.  Coupling reactions 
and deprotections were monitored by the Kaiser reaction unless otherwise noted:  
the Kaiser test was performed on a small number of beads that were transferred 
to a glass culture tube and washed with ethanol 3 times. To the beads was then 
added 2 drops each, of the three following solutions: 1) potassium cyanide (2% 
v/v of a 0.1 mM aqueous solution in pyridine); 2) ninhydrin (5% w/v) in ethanol; 3) 
phenol (20 % w/v) in ethanol.  The small sample of beads was then placed in a 
small boiling water bath, and monitored for color change for less than 5 minutes.  
A positive test results from ninhydrin reacting with free amines on the beads 
indicated by strong blue color, while protected amines result in a negative test 
and lack color change.  Boc deprotection was achieved in the presence of 20% 
TFA in dichloromethane; Fmoc deprotections were performed in the presence of 
20% piperidine in DMF.   
 After each coupling and deprotection step the resin was washed with 10 x 
DMF (5 bead volumes) followed by 10 x DMF/THF (1:1; 5 bead volumes).  Once 
the synthesis was complete, the resin was washed with 10 x DMF (5 bead 
volumes) 10 x DMF/THF (1:1; 5 bead volumes), 10 x THF (5 bead volumes), 
followed by 10 x ethyl ether (5 bead volumes).  The resin was then air-dried and 
transferred to a small glass vial, and could be stored in a desiccator at 4 °C.  The 
SAHA-based CIDs were cleaved from the resin in the presence of TFA (1 mL) 
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and DCM (1 mL) with shaking for 1.5 hours93,95.  The solution was then filtered 
through glass wool stuffed in a Pasteur pipet and rinsed with DCM into a glass 
vial.  The solution was then frozen and the solvent was removed under reduced 
pressure.  The final compounds were dissolved in DMSO and diluted 50% with 
water and filtered using a 0.45 μm syringe filter (Andwin Scientific catalog 
number NC9132669) for high pressure liquid chromatography (HPLC) 
purification. 
 HPLC was performed on a Waters 1525 binary HPLC pump with 
photodiode detector.  SAHA-based CIDs were purified on a semi-preparative 
reverse phase C18 column (10 x 250 mm, 5 μ; Grace Altima, catalog number 
88063, or Restek Ultra II, catalog number 9604577) with HPLC grade Acetonitrile 
and deionized distilled water (0.1% TFA) that was filtered through a 0.45 μm 
PVDF filter membrane (Pall catalog number 66480).  The HPLC system was 
washed with 40 column volumes of 0.05% EDTA solution in a water/methanol 
(9:1), followed by 40 column volumes of neutral water to remove residual iron 
from the instrument and column.101  The purified SAHA-based CIDs were 
collected in “iron-free” glassware treated with 6 M hydrochloric acid overnight, 
and rinsed with distilled water.  MALDI TOF spectra were taken on a Bruker 
Daltronics Ultraflex; HRMS spectra were taken on a Waters LCT Premier XE ESI-
LC–MS TOF.  Spectra and HPLC injections can be found in Appendix A.  
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2.5.2 Solid-Phase SAHA-Based CID Syntheses 
 
SAHA-biotin CID A (22).  Hydroxylamine Wang resin (2 mmol/g, 100 mg, 0.2 
mmol) was presoaked in THF (5 bead volumes, about 3 mL). Once the beads 
swelled, the solvent was removed and Boc protected suberoyl anilide 29 (225 
mg, 0.6 mmol) and TBTU (193 mg, 0.6 mmol) were added to the vessel as 
solids, and THF/DMF solvent system was added to 5 bead volumes.  Finally, 
DIPEA (0.209 mL, 1.2 mmol) was added, and the beads were shaken overnight.  
In later coupling reactions the progress is monitored by the Kaiser test, which 
tests positively to free amines, but the hydroxylamine is not sensitive to the test92 
and so the beads were left to couple overnight.  After at least 16 hours, the beads 
were washed (see general methods above).  Boc deprotection was achieved in 
the presence of 5 bead volumes of 20% trifluroacetic acid (TFA) in 
dichloromethane (2 x 5 minutes) and carefully monitored by the Kaiser test. Once 
the resin had been successfully deprotected, amide coupling reactions were 
performed iteratively first by adding linker 24 (213mg, 0.6 mmol), followed by 
biotin 23 (147mg, 0.6 mmol), both in the presence of TBTU (193 mg, 0.6 mmol) 
and DIPEA (0.20 mL, 1.2 mmol) in THF/DMF (1:1; 5 bead volumes);  reactions 
times were around 2-3 hours following Scheme 2.9.  The final compound (22) 
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was obtained after HPLC purification at 3 mL/min (10 x 250 mm, 5 μ; Grace 
Altima) with a gradient of H2O (containing 0.1% TFA) to CH3CN of 95:5 to 75:25 
over 10 min, followed by gradient to 65:35 over 20 minutes (tR 18.5 min).  This 
compound was very unstable, resulting in several peaks in the HLPC reinjection 
(see Appendix A.13) and only limited characterization was obtained (MALDI-
TOF, data not shown).   
 
 
SAHA-Biotin CID B (36).   
Method A (Scheme 2.10) 
Following the same synthetic method used for synthesis of SAHA-biotin 
CID A (22), hydroxylamine Wang resin (1.9 mmol/g, 100 mg, 0.2 mmol) was 
coupled to Boc protected suberoyl anilide 33 (253 mg, 0.6 mmol) in the presence 
of TBTU (193 mg, 0.6 mmol) and DIPEA (0.209 mL, 1.2 mmol) in THF/DMF (1:1, 
5 bead volumes).  After at least 16 hours, the beads were washed 10 times with 
DMF (5 bead volumes). Boc deprotection was achieved in the presence of 5 
bead volumes of 20% trifluroacetic acid (TFA) in dichloromethane (2 x 5 minutes) 
and carefully monitored by the Kaiser test.  Once the resin had been successfully 
deprotected, amide coupling reactions were performed iteratively using 3 
equivalents of carboxylate first by adding linker 24 (213mg, 0.6 mmol), followed 
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by biotin 23 (147mg, 0.6 mmol), both in the presence of TBTU (193 mg, 0.6 
mmol) and DIPEA (0.20 mL, 1.2 mmol) in THF/DMF (1:1; 5 bead volumes) with 
reactions times around 2-3 hours following Scheme 2.10. The final compound 
(36) (3.8 mg, 2.8%) was obtained after HPLC purification at 3 mL/min (10 x 250 
mm, 5 μ; Grace Altima, catalog number 88063) with a gradient of H2O 
(containing 0.1% TFA) to CH3CN of 95:5 to 75:25 over 10 min, followed by 
gradient to 71:19 over 20 minutes (tR 22 min).  Characterization of this compound 
is listed in Method B (below). 
 
Method B (Scheme 2.13) 
Suberic acid monomethyl ester 38 (0.107 mL, 0.6 mmol) was coupled to 
hydroxylamine Wang resin (1.9 mmol/g, 105 mg, 0.2 mmol) in the presence of 
TBTU (193 mg, 0.6 mmol) and DIPEA (0.20 mL, 1.2 mmol) in THF/DMF (1:1; 5 
bead volumes).  After at least 16 hours, the beads were washed 10 x THF/DMF 
(1:1, 5 bead volumes) followed by saponification of the methyl ester in the 
presence of saturated lithium hydroxide and THF (1:2, 3 mL total) for 8 hours with 
shaking96.  After saponification, the beads were washed 10 times with water (5 
bead volumes), 10 times with DMF (5 bead volumes), soaked in THF for 30 
minutes, and washed 10 x THF/DMF (1:1).  Fmoc protected diamine 37 (215 mg, 
0.6 mmol) was then coupled to the bead as described above with shaking 
overnight in the absence of a Kaiser test, followed by washing.  Fmoc 
deprotection was performed in the presence of 20% piperidine in DMF (2 x 10 
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min) and monitored by the Kaiser test.  Amide coupling reactions and Fmoc 
deprotections were performed iteratively following Scheme 2.13 first by adding 
linker 24 (213mg, 0.6 mmol), followed by biotin 23 (147mg, 0.6 mmol), both in the 
presence of TBTU (193 mg, 0.6 mmol) and DIPEA (0.20 mL, 1.2 mmol) in 
THF/DMF (1:1; 5 bead volumes).  The final compound (36) (10.5 mg, 7.7%) was 
obtained after HPLC purification at 5 mL/min (10 x 250 mm, 5 μ; Restek Ultra II) 
with a gradient of H2O (containing 0.1% TFA) to CH3CN of 95:5 to 78:22 over 10 
min, followed by gradient to 77:23 over 20 minutes (tR 16 min).  HRMS (ESI-LC–
MS, m/z): [M+H]+ for C32H52N6O8S 679.3489, found: 679.3488. 
 
 
SAHA-MTX (41).  Following the Method B for the synthesis of SAHA-biotin CID B 
(36), hydroxylamine Wang resin (132 mg, 0.2 mmol) was coupled to suberic acid 
monomethyl ester 38 (0.107 mL, 0.2 mmol) followed by saponification of the 
methyl ester with saturated lithium hydroxide and THF (1:2, 3 mL total) for 8 
hours with shaking.  After saponification, the beads were washed 10 times with 
water (5 bead volumes), 10 times with DMF (5 bead volumes), then soaked in 
THF (10 bead volumes) for 30 minutes, and washed with 10 x THF/DMF (5 bead 
volumes).  Amide coupling reactions and Fmoc deprotections were performed 
iteratively following Scheme 2.16.  Fmoc protected diamine 37 (215 mg, 0.6 
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mmol) was then coupled to the bead as described above with shaking overnight 
in the absence of a Kaiser test, followed by washing.  Fmoc deprotection was 
performed in the presence of 20% piperidine in DMF (2 x 10 min) and monitored 
by the Kaiser test.  Amide coupling reactions and Fmoc deprotections were 
performed iteratively following Scheme 2.13 first by adding linker 27 (213mg, 0.6 
mmol), followed by Fmoc-Glu-OtBu (46) (255 mg, 0.6 mmol) and finally MTX 
fragment (42) (195mg, 0.6 mmol) in the presence of TBTU (193 mg, 0.6 mmol) 
and DIPEA (0.20 mL, 1.2 mmol) in THF/DMF (1:1; 5 bead volumes).  The final 
compound (41) (9.3 mg, 5.2%) was obtained after HPLC purification at 3 mL/min 
(10 x 250 mm, 5 μ; Restek Ultra II) with an isocratic system of H2O (containing 
0.1% TFA) to CH3CN of 80:20 (tR 22 min).  HRMS (ESI-LC–MS, m/z): calculated 
[M+H]+ for C42H57N12O10 889.4321, found: 889.4299. 
 
2.6 General Biochemical Methods 
2.6.1 General Materials 
 Reagents were generally purchased from Fisher Scientific, Acros Organics 
or Sigma Aldrich unless otherwise noted; complete supplemented media (CSM) 
dropout powder was purchased from Bio101 Systems; Yeast Nitrogen Base 
without amino acids, BactoTM Agar, BactoTM peptone and Yeast Extract were 
purchased from Difco.  
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2.6.2 General Equipment 
 The Pflum lab is equipped with standard biochemical equipment including 
centrifuges (Eppendorf models 5415D and 5810R), yeast incubator/shaker 
(Barnstead labline MaxQMini 4000), bacterial incubator/shaker (New Brunswick 
Scientific C25 Incubator Shaker Classic Series), a Tecan GENios Plus 
spectrophotometer, and a FisherBiotech midi horizontal gel electrophoresis 
system. 
 
2.6.3 Preparation of Chemocompetent XL1 Blue E. coli 
 The yeast expression plasmids were replicated in the XL1 blue strain of E. 
coli to produce large amounts of plasmid.  To enable plasmid transformation into 
these cells, they were treated with calcium chloride to induce chemocompetency.  
A liquid culture (25 mL) of XL1 blue in LB media (1% peptone, 0.5% yeast 
extract, 1% sodium chloride) was grown overnight at 37 °C with shaking at 250 
rpm.  The following day 4 mL of this culture was seeded into 400 mL of LB 
media.   The culture was incubated under the same conditions as above until the 
absorbance at OD600 was approximately 0.375.  The culture was transferred (in 
50 mL portions) to pre-chilled 50 mL centrifuge tubes, and cooled on ice for 5-10 
minutes.  The cells were then collected by centrifugation at 4000 rpm for 10 
minutes followed by aspiration of the media.  The cells were then washed in 10 
mL of cold calcium chloride solution (60 mM CaCl2, 10 mM PIPES, 15% v/v 
glycerol).  Cells were collected as above, and washed one more time with 10 mL 
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of cold calcium chloride solution.  Finally, the cells were resuspended in 2 mL of 
calcium chloride solution and aliquots (250 µL, approximately 3 transformations) 
were stored at -80 °C. 
 
2.6.4 Bacterial Plasmid Transformation  
 Yeast expression plasmids were transformed into chemocompetent XL1 
blues E. coli (section 2.6.3) for plasmid biosynthesis.  Plasmid dissolved in water 
(1 µL, <0.5 mg/mL) was added to a centrifuge tube containing chemocompetent 
cells (70 µL), which were previously thawed on ice.  After incubation on ice for 30 
minutes, the cells were heat-shocked for 60-90s at 42°C in a heat block and then 
placed on ice for 2 minutes.  LB media (1 mL) was added to the cells, followed by 
incubation at 37 °C for 60 minutes with shaking at 250 rpm.  The cells were then 
collected by centrifugation for 10 min at 13200 rpm.  The supernatant, except for 
100 µL, was removed by aspiration.  The cells were resuspended in the 
remaining liquid, and plated on LB containing 2% BactoTM agar and the 
appropriate selection antibiotic (50 µg/mL ampicillin or kanamycin).  After 
overnight incubation, single colonies were restreaked onto LB plates containing 
the appropriate antibiotic selection.  Single colonies from the double selection 
were then cultured for plasmid biosynthesis (section 2.6.5). 
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2.6.5 Plasmid Mini-Prep 
 A single colony of XL1 blue containing the plasmid of interest was cultured 
in 12 mL of LB media containing the appropriate antibiotic selection (50 µg/mL 
ampicillin or kanamycin).  The culture was grown overnight at 37 °C with 250 rpm 
shaking.  Cells were collected by successive centrifugation (1 min, 13200 rpm) in 
two 1.5 mL epitubes, removing the supernatant by aspiration after each 
centrifugation.  The cells were resuspended and combined in 300 µL of P1 buffer 
(QIAgen, 50mM Tris-Cl, pH 8.0, 10 mM EDTA, 100 µg/mL RNAse A). P2 buffer 
(QIAgen, 300 µL; 200 mM sodium hydroxide, 1% SDS) was added and mixed by 
inversion prior to incubation for 5 minutes at room temperature.  P3 buffer 
(QIAgen, 3.0 M potassium acetate, pH 5.5) was pre-cooled on ice, and then 300 
µL was added to the lysed cells, which was mixed by inversion and incubated on 
ice for 5 minutes.  The cell debris was removed by centrifugation (10 minutes x 
13200 rpm), and the supernatant was added to a chilled tube containing 540 µL 
of isopropanol.  After 5 minutes of incubation on ice, the DNA was collected by 
centrifugation (10 minutes x 13200 rpm).  The supernatant was removed by 
aspiration, and the DNA pellet was air-dried to evaporate the remaining 
isopropanol.  The DNA was redissolved in 20 µL of water and stored at -20 °C. 
 
2.6.6 Preparation of Salmon Sperm DNA 
Transformation of plasmids into yeast is aided by inclusion of small 
intercalating DNA from salmon sperm.  Dry salmon sperm DNA (250 mg, Sigma 
  
89 
catalog number 31149) was added to 25 mL of water (to give 10 mg/mL) and 
dissolved by shaking overnight.  The following day, the solution was boiled in a 
water bath for 15 minutes or until homogeneous solution had been reached, 
vortexing if necessary.  The solution was cooled to room temperature, and 1 mL 
aliquots were stored at – 20 °C.  Prior to use for yeast transformations, the 
solution was boiled for 5 min, and then cooled on ice for 5 minutes. 
 
2.6.7 Yeast Transformation of Plasmid DNA 
Yeast transformations were performed by a combination of treating cells to 
make them chemocompetent, and using the salmon sperm DNA to aid DNA 
transformation.  A transformation solution (for 5 tranformations) was prepared by 
thoroughly mixing (vortexing if necessary) 333 µL of 60% PEG 3350, 50 µL of 1M 
dithiothreitol (DTT), 50 µL of 2N lithium acetate, and 67 µL of water (to final 
concentration 40% PEG 3350, 100 mM DTT, 0.2 N LiAc).  Cells from a fresh 
yeast plate (1 cm2, 2 days growth) were transferred to the transformation solution 
using a sterilized Pasteur pipet and stirred in thoroughly.  This mixture of cells in 
transformation solution (100 μL) was combined with salmon sperm DNA (10 µL, 
10 mg/mL) and plasmid DNA (1 μL, 0.5 mg/mL) and mixed by flicking the 
epitubes.  The tubes were incubated on ice for 30 minutes, then at 43 °C in a 
heat block for 45 minutes, and then returned to ice for 5 minutes.  The mixture 
was then plated on complete supplemented medium (CSM) containing 2% Bacto-
agar with amino acid dropout selection for the plasmid(s) of interest (see Table 
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2.1) and incubated at 30 °C.  After several days (usually 4 to 7 days), single 
colonies were selected and restreaked onto plates with the appropriate dropout 
selection media to double select colonies containing the plasmid of interest, and 
grown at 30 °C for 2-3 days. The plates were then stored at 4 °C wrapped in 
parafilm for future use. 
 
Table 2.1. Description of Yeast Expression Plasmids. 
Plasmid Yeast 
Selection 
Bacterial 
Selection 
Yeast Expression Source 
pSH18-34 URA3 Amp lacZ gene directed 
by 8 lexA operators 
for β-gal expression 
Peterson64,99 
pSH17-4 HIS3 Amp LexA-B42 Origene 
pMW112 URA3 Kan lacZ gene directed 
by 8 lexA operators 
for β-gal expression 
Cornish63 
pSA1 T7-SA B42 TRP1 Amp T7 tagged SA-B42 Peterson64,99 
pSA1 Rpd3-B42 TRP1 Amp Rpd3-B42 This work 
pSA1 HDAC1-
B42 
TRP1 Amp HDAC1-B42 This work 
pNLexA-HDAC1 HIS3 Amp LexA-HDAC1-VP16 M.K.H. Pflum 
 
 
2.6.8 Yeast Three Hybrid Assay 
 Single colonies of the FY250 yeast strain (from the Peterson 
laboratory64,65) or V760 strain (from the Cornish Laboratory67, HIS3 selection) 
containing Y3H plasmids were grown overnight in 3 mL of CSM selection media 
(containing 2% raffinose) with appropriate amino acid complementation (see 
Table 2.1 for plasmid selection and Figures 2.7 and 2.8 for plasmid 
combinations).  This overnight culture (50 µL) was added to a 96 well plate 
(Costar flat bottom transparent, catalog number 07-200-656) containing 197.5 µL 
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of CSM media (containing 1% raffinose, 2% galactose) and final concentration 
100 µM SAHA-based CIDs (SAHA-biotin B (36) or SAHA-MTX (41), 2.5 µL of 10 
mM; 1% DMSO final concentration), or DMSO (1% final concentration) for 
control.  The SAHA-based CIDs were used at the highest soluble concentration.  
For trials that included zymolyase, 5 µL of 5U/µL was added (for 25U per 
reaction) in lieu of 5 µL of media.  The cultures were incubated at 30 °C with 
shaking at 200 rpm for at least 5 hours.  The absorbance of the culture was 
measured at OD600.  The 250 µL of culture was then transferred to an epitube, 
and the cells were collected by centrifugation at 4400 rpm for 5 minutes.  The 
media was then removed by aspiration, and the cells were resuspended in 200 
µL of Z buffer (0.06 M Na2HPO4 0.04 M NaH2PO4, 0.1 M KCl, 0.001 M MgSO4, 
0.05 M β-mercaptoethanol, pH 7.0) and treated with 1 drop of chloroform and 2 
drops of 0.1% SDS to induce poration to allow the reagents to diffuse through the 
yeast membrane81.  Samples were then vortexed for at least 30 seconds, and 
100 µL of ο-nitrophenyl-β-D-galactoside (ONPG, 4 mg/mL in 0.1 M phosphate 
buffer, pH 7.5) was added to each tube.  Samples were incubated at 30 °C.  
Once samples had developed a yellow color (30-60 minutes), the reaction was 
quenched with sodium carbonate (1M, 50 µL).  Cell debris was removed by 
centrifugation (13200rpm, 5 minutes) and the absorbance (OD420) of the clarified 
supernatant (150 µL) was measured.  Values for the ONPG assay were 
expressed as units of β-galactosidase activity = (OD420)/[OD600 x volume of 
culture (mL) x time (minutes)].  For a typical assay, the volume of culture used to 
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measure OD600 was 0.25 mL and the time for ONPG was the time between 
addition of ONPG and quenching with sodium carbonate (typically 30-60 
minutes). 
 
2.7 Construction of HDAC-B42 Yeast Expression Plasmids 
Yeast expression plasmids encoding for HDAC1-B42, HDAC1(H141A)-
B42 (catalytically inactive HDAC1 mutation) and Rpd3-B42 (Rpd3 is the yeast 
HDAC class I homolog) hybrid proteins were cloned for use as the “bait” in the 
Y3H assay.  Genes for these hybrid proteins were amplified by polymerase chain 
reaction (PCR) (section 2.7.3) and inserted into linearlized plasmid (section 2.7.4) 
through homologous recombination in chemocompetant KC8 E. coli102 (section 
2.7.1 and section 2.7.4). 
 First plasmid pSA1 EcoRI-HDAC1-B42-EcoRI-XhoI (Figure 2.9) was 
created from pSA1 T7-SA (TRP1, Pgal1, AdhT, 2μ, ampR) with an NcoI restriction 
site between the DNA encoding for HDAC1 and DNA for B42.  To facilitate 
cloning other HDAC-B42 fusion proteins, pSA1 EcoRI-HDAC1-B42-EcoRI-XhoI 
was further modified to remove the second EcoRI restriction site, which also 
restored the HA tag on the C-terminus of B42 fusion protein to create plasmid 
pSA1 HDAC1-B42 (Figure 2.10).  Plasmids pSA1 HDAC1(H141A)-B42 and pSA1 
Rpd3-B42 were cloned by inserting HDAC1(H141A) or Rpd3 cDNA respectively, 
into pSA1 HDAC1-B42 after EcoRI/NcoI restriction digest to remove HDAC1 
(section 2.7.2).  
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Figure 2.9.  Plasmid Map of pSA1 EcoRI-HDAC1-B42-EcoRI-XhoI.  
First yeast expression plasmid cloned for the expression of HDAC1-B42 
under control of a GAL1 promoter and Adh termination domain. Relevant 
restriction sites are displayed including EcoRI site before HDAC1 and 
immediately after  
EcoRI
NcoI
EcoRI
XhoI
7350bp
pSA1 EcoRI-HDAC1-B42 EcoRI-XhoI
GAL1
B42
ADHT
2 um origin
TRP
AMP
pUC ori
HDAC1
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Figure 2.10.  Plasmid Map of pSA1 HDAC1-B42.  Yeast expression 
plasmid of HDAC1-B42 lacking the second EcoRI restriction site.  
Expreesion of HDAC1-B42 in under control of a GAL1 promoter and Adh 
termination domain.  Other important features include ampicillin resistance 
in bacteria, and TRP1 selection in yeast. 
  
EcoRI
NcoI
XhoI
7350bp
pSA1 HDAC1-B42
GAL1
B42
ADHT
2 um origin
TRP
AMP
pUC ori
HDAC1
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2.7.1 Preparation of Chemocompetant KC8 E. coli 
 Cloning was performed using homologous recombination in chemically 
competent KC8 E. coli.  Similar to yeast, bacteria have been used for their native 
in vivo homologous recombination function102-104.  The KC8 strain was a gift from 
the Finley lab at Wayne State University, who has previously shown this strain is 
efficient for high-throughput recombinant cloning102.   Cells were prepared for 
chemocompetency prior to DNA transformation.  A 5 mL liquid culture of KC8 
was grown overnight in LB media at 37 °C with 250 rpm shaking.  The culture 
was then added to 500 mL of LB media, and incubated at 37 °C with 250 rpm 
shaking until the OD600 was 0.5, or about 3 hours.  The cells were collected by 
centrifugation at 3500 rpm for 15 min at 4 °C, and the media was removed.  The 
cells were resuspended in 25 mL of pre-chilled TSB (LB adjusted to pH 6.1 with 
dilute aqueous HCl, 10% (w/v) PEG 3400, 5% (v/v) DMSO, 10% (v/v) glycerol, 10 
mM MgCl2, 10 mM MgSO4), and incubated for 10 minutes on ice.   Aliquots (250 
µL, approximately 5 transformations) were flash frozen in an ethanol-dry ice 
solution and stored at -80 °C. 
 
2.7.2 Restriction Enzyme Digest 
Plasmids were linearlized using bacterial restriction enzymes prior to 
homologous recombination105.  Restriction enzymes (Promega: EcoRI, XhoI and 
NcoI; catalog numbers: R6011 R6161; R6513 respectively) and plasmids (for 
details see Table 2.2) were combined in 1X Buffer H (Promega) to a total volume 
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of 20 μL (0.1 mg/mL BSA), and incubated at 37 °C with shaking at 250 rpm.  To 
prevent the plasmids from religating after digestion, calf intestinal phosphatase (1 
µL of 10000U/mL, NEB cat # M0290S) and 10X NEB buffer 3 (2 µL, 1 M NaCl, 
500 mM Tris-HCl, 100 mM MgCl2, 10 mM dithiothreitol, pH 7.9) were added to 
the reaction after 2 hours, and was incubated as above for an additional 60 
minutes.  The linearlized plasmid was purified by gel electrophoresis [1% 
agarose in Tris-Acetate-EDTA buffer (TAE; 40 mM Tris, 20 mM acetate, 1 mM 
EDTA, pH 8.5, 0.5 μg/mL ethidium bromide)] for 60 minutes at 200V, extracted 
using QIAgen gel extraction spin kit (cat # 28704) and eluted into 30 µL of water 
for use in homologous recombination (section 2.7.4). 
 
Table 2.2.  Description of Restriction Enzyme Digest Reactions. 
Target plasmid Parent plasmid Restriction Enzymes 
pSA1 EcoRI-HDAC1-
B42-EcoRI-XhoI 
pSA1 T7-SA (1μL, 0.5 
μg/μL) 
EcoRI; 1μL of 10U/μL 
XhoI; 1μL of 10U/μL 
pSA1 HDAC1-B42 pSA1 EcoRI-HDAC1-B42-
EcoRI-XhoI (1 μL, 0.5 μg/μL) 
NcoI; 1μL of 10U/μL 
XhoI; 1μL of 10U/μL 
pSA1 
HDAC1(H141A)-B42 
pSA1 HDAC1-B42 (1μL, 0.5 
μg/μL) 
EcoRI; 1μL of 10U/μL 
NcoI; 1μL of 10U/μL 
pSA1 Rpd3-B42 pSA1 HDAC1-B42(1 μL, 0.5 
μg/μL) 
EcoRI1μL of 10U/μL  
NcoI; 1μL of 10U/μL 
 
 
2.7.3 Polymerase Chain Reaction (PCR) 
DNA encoding for HDAC-B42 hybrid proteins were amplified using a PCR 
touch down program.  The PCR insert for EcoRI-HDAC1-B42-EcoRI-XhoI was 
created in a two-step PCR sequence.  In the first step, HDAC1 sequence was 
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amplified from p424 HDAC1-LexA plasmid106 using forward primer pSA1-EcoRI-
HDAC1(for) 5ʼ-
AACGTCAAGGAGGAATTAACTATAGAATTCATGGCGCAGACGCAGGGCACC 
and reverse primer HDAC1-NcoI-B42(rev) 5ʼ-
CTTTTTTGGAGGAGCACCCATCCATGGGGCCAACTTGACCTCCTCCTT.  B42 
cDNA was amplified from the Peterson plasmid pSA1 T7-SA65 to include the 
nuclear localization signaling domain using forward primer HDAC1-NcoI-B42(for) 
5ʼ-AAGGAGGAGGTCAAGTTGGCCCCATGGATGGGTGCTCCTCCAAAAAG 
and reverse primer pSA1(rev) 5ʼ-
GAAGTGTCAACAACGTATCTACCAACGATTTGACCC. Samples were prepared 
on ice in 0.5 mL epitubes by combining in order: water (30 µL), DMSO (5 µL), 
10X Pfu buffer (5 µL of 200 mM Tris, 100 mM (NH4)2SO4, 100 mM KCl, 1% Triton 
X-100, 20 mM MgSO4, 1 mg/ml BSA, pH 8.8), DNA plasmid template (1 μL of 0.5 
µg/μL), forward (1 μL of 12.5 pmol/μL) and reverse primers (1 μL of 12.5 
pmol/μL), and dNTPs (5 μL of 10 mM; 2.5mM of each base).  Samples were 
mixed thoroughly and centrifuged briefly, then heated in thermocycler (Eppendorf 
Mastercycler Gradient) for 1 minute at 95 °C prior to addition of Pfu enzyme (2 
µL, for a final volume of 50 μL).  After addition of the enzyme, the touch down 
program began with 10 cycles with decreasing annealing temperatures as 
follows: 1 minute at 95 °C to disrupt all binding interactions, followed by 1 minute 
at annealing temperature, and 2 minutes at 72 °C for DNA elongation.  The initial 
annealing temperature was 65 °C and final annealing temperature of 55 °C. 
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Following the initial 10 cycles, 25 cycles matching the tenth cycle at the final 
annealing 55 °C were performed.  The PCR cycles ended with a 10 minute 
elongation period at 72 °C before cooling to 4 °C.  
A second PCR step was used to create the full length EcoRI-HDAC1-B42-
EcoRI-XhoI insert for homologous recombination.  Extracted PCR products of 
HDAC1 cDNA (0.5 μL from above) and B42 (0.5 μL from above) were combined 
in a 0.5 mL epitube on ice.  Water (30 µL) was added followed by DMSO (5 µL), 
10X Pfu buffer (5 µL), forward primer pSA1-EcoRI-HDAC1(for) (1 μL of 12.5 
pmol/μL), reverse primer pSA1(rev) (1 μL of 12.5 pmol/μL), and dNTPs (5 μL of 
10 mM; 2.5mM of each base).  Samples were mixed thoroughly and centrifuged 
briefly, then heated in thermocycler (Eppendorf Mastercycler Gradient) for 1 
minute at 95 °C prior to addition of Pfu enzyme (2 µL, for a final volume of 50 μL).  
The same touchdown program was used in the second PCR step with an initial 
annealing temperature of 65 °C and final annealing temperature of 55°C.   The 
PCR product (10 μL) was verified by gel electrophoresis (as above), but the 
majority of (40 μL) was purified using QIAquick PCR purification kit (catalog 
number 28104), and eluted into 30 µL of water. The purified PCR sample was 
transformed immediately with fresh restriction digest product (section 2.7.2) into 
KC8 E. coli for homologous recombination (section 2.7.4). 
The HDAC-B42 PCR insert for cloning HDAC1-B42 lacking the second 
EcoRI restriction site, was amplified from plasmid pSA1 EcoRI-HDAC1-B42-
EcoRI-XhoI using forward primer pSA1-EcoRI-HDAC1(for) and new reverse 
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primer B42-XhoI-pSA1(rev) 5ʼ-
CAAAGCTTCTCGACTCACTCGAGGGGAGAGGCATAATCTG.  The PCR 
samples were prepared following the same protocol as above.  Three samples 
were prepared on ice in 0.5 mL epitubes by combining in order: water (30 µL), 
DMSO (5 µL), 10 x Pfu buffer (5 µL) DNA plasmid template (1 μL of 0.5 µg/μL), 
forward (1 μL of 12.5 pmol/μL) and reverse primers (1 μL of 12.5 pmol/μL), and 
dNTPs (5 μL of 10 mM; 2.5mM of each base).  Samples were mixed thoroughly 
and centrifuged briefly, then heated in thermocycler (Eppendorf Mastercycler 
Gradient) for 1 minute at 95 °C prior to addition of Pfu enzyme (2 µL, for a final 
volume of 50 μL).  After addition of the enzyme, the touch down program began 
as above with an initial annealing temperature of 65 °C and final annealing 
temperature of 55 °C.  The three PCR samples were combined and purified by 
gel electrophoresis (as above) for 60 minutes at 200V, then extracted into 30 µL 
of water using QIAquick gel extraction spin kit (catalog number 28704).  The 
purified PCR sample was transformed immediately with fresh restriction digest 
product (section 2.7.1) into KC8 E. coli for homologous recombination (section 
2.7.4).  
For cloning Rpd3-B42 encoding plasmid into pSA1 HDAC1-B42, the Rpd3 
insert was amplified from plasmid YEplac112-Rpd3-LexA-FLAG106 with the 
forward primer pSA1-EcoRI-Rpd3(for) 5ʼ-
CGTCAAGGAGGAATTAACTATAGAATTCATGAGTTATGAAGC and reverse 
primer Rpd3-NcoI-B42(rev) 5ʼ-
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GGAGCACCCATCCATGGATAGAATTCATTGTCATGCTCAACATGTA following 
the method above, but using an initial annealing temperature of 70 °C and final 
annealing temperature 60 °C.  In a similar manner, HDAC1(H141A) insert was 
amplified from p424 HDAC1(H141A)-LexA (modified by Sujith Weerasinghe from 
p424 LexA-HDAC1106) using forward primer pSA1-EcoRI-HDAC1(for) and 
reverse primer HDAC1-NcoI-B42(rev) with initial annealing temperature 65 °C 
and final annealing temperature 55 °C. 
 
2.7.4 Homologous Recombination in KC8 cells 
 For this application PCR inserts were combined with linearlized plasmid in 
different ratios in chemocompetent KC8 E. coli cells (section 2.7.1).  The most 
successful results were obtained when chemocompetant KC8 cells (50 µL, 
section 2.7.4) pre-thawed on ice were combined with 5 µL of PCR insert (section 
2.7.3) and 5 µL of linearlized plasmid (section 2.7.2) in a 1X KCM buffered 
solution (final concentration 0.1 M potassium chloride, 30 mM calcium chloride, 
50 mM magnesium chloride).  The cells were incubated on ice for 20 minutes, 
followed by heat shock at 42 °C for 30 to 45 seconds and cooled on ice for an 
additional 5 minutes.  500 µL of LB media was added and cells were incubated at 
37 °C with shaking at 250 rpm for 60 to 90 minutes. Cells were collected by 
centrifugation at 13200 rpm for one minute; the solution was removed except for 
about 150 µL.  The cells were resuspended in the remaining liquid and plated 
onto LB agar plates (containing 20 µg/mL kanamycin for KC8 selection and 50 
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µg/mL ampicillin for selection of new plasmids).  After overnight incubation at 37 
°C, colonies were restreaked for double selection on LB plates (as above).  
Several double selected colonies were then mini-prepped (section 2.6.3) and 
analyzed by restriction digest and PCR before submitting for sequencing. 
Successfully cloned plasmids were transformed into XL1 blues for larger scale 
plasmid synthesis. 
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CHAPTER 3 
IN VITRO HDAC INHIBITOR ASSAY DEVELOPMENT 
 
3.1 In vitro Competitive Inhibitor Screening 
3.1.1 Introduction to Competitive Inhibitor Screening In Vitro 
Due to their role in regulating gene expression, Class I HDAC enzymes 
have been identified as targets for cancer therapeutics.  Advancement in the 
discovery of selective HDAC inhibitors against Class I enzymes has been limited 
by a lack of technology for screening inhibitors against individual HDAC isoforms; 
a high-throughput screening method could significantly improve current methods 
of identifying selective HDAC inhibitors.  A competitive inhibitor screen was 
developed using a yeast three hybrid system, but the impermeability of SAHA-
based CIDs towards the yeast cells presented significant obstacles towards 
screening HDAC inhibitors in yeast (Chapter 2). 
As an alternative to screening HDAC inhibitors using the Y3H system, this 
Chapter outlines a competitive HDAC inhibitor screen in vitro.  HDAC inhibitors 
will be screened from HeLa lysates and probed using antibodies, which 
specifically bind to individual HDAC isoforms (see section 3.2.3 for details).  A 
major advantage to this method over the Y3H is that competitive inhibitors will be 
screened only for binding interaction without the complication of yeast cell 
permeability.  In addition, there is no need to grow yeast overnight, resulting in a 
shortened assay that can be performed in a few hours.  
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The in vitro competitive HDAC inhibitor assay was inspired by previous 
work done by Ambit biosciences in their development of an in vitro selective 
kinase inhibitor assay (section 1.4.1).83,107  The kinase in vitro assay was 
developed around a CID composed of biotin linked to a non-selective kinase 
inhibitor, similar to the SAHA-biotin CIDs developed in Chapter 2 for the Y3H 
assay (section 2.2.4).  In the assay, individual kinase proteins were expressed on 
T-7 bacteriophage produced in E. coli followed by PCR amplification for detection 
of unbound (or competitively inhibited) proteins.  This method was not applicable 
to HDAC proteins due to improper folding of HDAC proteins when expressed in 
bacterial systems, which we verified prevents SAHA-biotin CID binding to HDAC1 
(section 3.2.2).  Alternatively, HDAC proteins could be isolated from HeLa lysates 
by immunoprecipitation (section 3.2.3).  
 
3.1.2 In vitro HDAC Inhibitor ELISA Assay 
Towards the goal of high throughput inhibitor screening, we developed an 
HDAC-based ELISA for screening HDAC inhibitors against individual HDAC 
isoforms.  For this application, the use of a SAHA-biotin CID allowed for isolation 
and detection of HDAC proteins from cellular lysates by taking advantage of the 
strong interaction between biotin and streptavidin (SA) or streptavidin analogs108.  
Using this method, secondary anti-rabbit antibody coated plates were coated with 
primary anti-HDAC1 antibody from rabbit (Figure 3.1).  The wells were then 
treated with HeLa lysates in the presence of SAHA-biotin CID B (36), followed by 
  
104 
streptavidin-horse radish peroxidase (SA-HRP) complex and HRP substrate, 
allowing for easy detection of the HDAC1 interaction with SAHA-biotin CID B (36) 
(Figure 3.1 A).  Competitive HDAC inhibitors could then be used to disrupt the 
HDAC binding to the complex, resulting in the SA-HRP complex being washed 
away, and a lack of signal (Figure 3.1 B).   
The HDAC-based ELISA was developed as a competitive screening tool 
for screening selective HDAC inhibitors against individual HDAC isoforms.  
Unlike the current fluorescence method for screening HDAC inhibitors, this assay 
would not monitor the inhibition of deactylase activity by inhibitors, but would 
represent binding affinity to HDAC proteins.  Significantly, this method would 
include isolation of individual HDAC isoforms, unlike the current assay, which 
includes all the HDAC proteins present in HeLa lysates and does not assess 
selectivity.  In addition, this assay would offer a widely accessible method for 
screening competitive HDAC inhibitors compared to the mass spectrometric 
analysis used to screen HDAC inhibitors in the in vitro screen discussed in 
section 1.4.2.   To assess the viability of the ELISA-based HDAC assay, SAHA-
Biotin CIDs (for synthesis see section 2.2.4) was used for isolation of HDAC 
proteins from cellular lysates using NeutrAvidin beads followed by western blot 
analysis (section 3.2.1), and ultimately for detection in an HDAC-dependent 
ELISA (section 3.2.4). 
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Figure 3.1.  HDAC Inhibitor ELISA.  Individual wells from 96-well plate 
represented; primary antibody represented by Y at bottom of the wells; 
HDACX represents the different HDAC proteins that could be isolated in 
this assay; HDAC proteins isolated from HeLa lysates.  A) In the presence 
of SAHA-Biotin CID, SA-HRP complex is recruited, and HRP substrate is 
cleaved resulting in a detectable signal.  B) In the presence of a 
competitive HDAC inhibitor, SA-HRP complex will be washed away, 
leading to a lack of signal  from the HRP substrate (Sub). 
  
HDACX
Sub.
HRP
SA
HDACX
WASH AWAY
LOSS OF SIGNAL
A B
= SAHA-Biotin
= Competitive
HDAC inhibitor
CID
CID
  
106 
3.2 Results 
3.2.1 CID Binding Using NeutrAvidin Beads 
As a proof of concept that the SAHA-biotin CID could be used to isolate 
HDAC proteins in vitro, NeutrAvidin beads were employed to precipitate HDAC 
proteins from cellular lysates.  HeLa lysates were used in these initial 
experiments because they are a common source of human HDAC proteins. 
Lysates were incubated with SAHA-biotin CID A (22) followed by NeutrAvidin 
beads (Figure 3.2 A) and analyzed by western blot analysis (Figure 3.2 B).  
Isolation of HDAC1 was shown to be dependent on the concentration of CID 
used, and was self-competed if a high concentration of CID was used; best 
results were obtained using lysates incubated with 1 μM SAHA-biotin CID, with 
less signal observed for lysates incubated with 10 μM CID, and no signal 
observed for lysates incubated with 100 μM SAHA-biotin CID (Figure 3.2 B). 
This method was then modified to pre-coat the NeutrAvidin beads with 
SAHA-biotin CID B (36) prior to treatment with HeLa lysate in order to eliminate 
self-competition, which is the same protocol used in the kinase selectivity assay 
(section 1.4.1). 83,84  First, we demonstrated that HDAC1 and HDAC2 bound non-
specifically to the NeutrAvidin beads in the absence of SAHA-biotin CID (Figure 
3.3 A, (-) SAHA-biotin CID lane), but this non-specific interaction could be 
avoided if lysates were first pre-cleared in the presence of NeutrAvidin beads 
prior to treatment with beads coated in SAHA-biotin CID B (Figure 3.3 B, (-) 
SAHA-biotin CID lane).  Using the pre-clearing method high abundant HDAC1-3, 
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Figure 3.2. Isolation of HDAC from lysates using SAHA-Biotin CID 
and NeutrAvidin beads.  A) Binding complex of SAHA-Biotin with HDAC 
and NeutrAvidin beads.  B) Western blot analysis (anti-HDAC1) of HDAC1 
isolated by NeutrAvidin beads with varying concentrations of SAHA-Biotin 
CID A.  
Biotin SAHA HDAC
NeutrAvidin
Coated Beads
A
B
Lysate
0 1 10 100
anti-HDAC1
CID (μM) 
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Figure 3.3. Isolation of HDAC Proteins From HeLa Lysates using 
SAHA-Biotin CID B Coated NeutrAvidin Beads.  Western blot analysis 
(antibodies indicated to the right of figure) of HDAC protein isolation with 
NeutrAvidin beads either in the absence of SAHA-biotin CID (-), or pre-
coated with 1 µM SAHA-Biotin CID B (36) (+).  A) HDAC1 and HDAC2 
isolation in the absence of pre-clearing HeLa lysates with NeutrAvidin 
beads; lysate lane is 20% loading of HeLa lysates.  B) Isolation of HDACs 
1-3, 5-7, and 10 from HeLa lysates pre-cleared with NeutrAvidin beads 
prior to pulldown experiment; lysate lane is 10% loading of HeLa lysates 
except for HDAC2 (20% loading).  
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6 and 10 were isolated using the SAHA-biotin CID (36), while HDACs 5 and 7 
were not isolated (Figure 3.3 B).  HDAC6 was isolated with high signal compared 
to the lysate control lane (10% loading) in relation to the other HDAC proteins, 
indicating that the SAHA-biotin CID B (36) may have higher affinity towards 
HDAC6 (further assessment with the HDAC activity assay required).  These 
results show a proof of concept that the SAHA-biotin CID is affective for isolation 
of individual HDACs 1-3, 6 and 10.  To allow access to the individual HDAC 
isoforms, antibody isolation using secondary antibodies in a high throughput 
plate-based ELISA was developed (Section 3.2.4).  
 
3.2.2 CID binding to HDAC1 expressed in BL21 E coli 
With the knowledge that SAHA-biotin CID was able to precipitate HDAC 
proteins from human cellular lysates, we next tried to precipitate human HDAC1 
expressed in BL21 strain of E coli, which could provide a facile expression of 
individual HDAC isoforms.  HDAC1 has previously been reported to lack activity 
when expressed in bacterial systems6, but whether this loss of activity affects 
inhibitor binding was still in question.  To answer this question, HDAC1 was 
expressed in the bacterial system, and lysates were incubated with various 
concentrations of SAHA-biotin CID followed by NeutrAvidin beads (Figure 3.4).  
This experiment confirmed that although HDAC1 is present in the lysates (Figure 
3.4, lysate lane), the SAHA-biotin CID was not effective in isolating these proteins 
(Figure 3.4, 1 µM, 10 µM and 100 µM SAHA-biotin CID lanes).  These results are  
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consistent with the improper folding of HDAC1 in bacterial expression systems 
that not only affects activity, but also inhibitor binding to the active site of HDAC1.  
An alternate method of isolating individual HDAC proteins was needed. 
 
 
Figure 3.4.  SAHA-Biotin CID Treated BL21 Lysates Expressing 
Human HDAC1.  Western blot analysis (anti-HDAC1) of HDAC1 from 
NeutrAvidin beads with varying concentrations of SAHA-Biotin CID. Lane 
1: lysate (5% loading), lane2: 0 µM CID; lane 3: 1 µM CID; lane 4: 10 µM 
CID; lane 5: 100 µM CID.  
 
 
 
3.2.3 Immunoprecipitation (IP) of Individual HDAC Proteins 
In order to obtain well-folded human HDACs from lysates, HeLa cells 
containing the majority of HDACs were used, and individual HDAC proteins were 
isolated by IP.  A limiting factor to this method is the known interactions of 
several of the HDAC isoforms with each other, which could give misleading 
results when screening inhibitors for isoform selectivity.  Specifically, HDAC1 and 
HDAC2 have been shown previously to co-IP from HeLa lysates.109  In addition, 
HDAC3 been shown to co-IP with Class IIb HDACs 4 and 7.110,111  The 
interaction between HDAC1 and HDAC2 was observed through co-IP, confirming 
the previously reported results (Figure 3.5 A).109   
Lysate 0 1 10 100 
CID (μM) 
anti-HDAC1 
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In order to screen individual HDAC isoforms, isolation of individual HDAC 
from complexes was required for accurate selectivity screening.  In an effort to 
isolate these proteins individually, lysates were pre-cleared with protein A 
agarose resin (used in the IPs to precipitate the antibodies) prior to IP.  Using this 
pre-clearing method, HDAC1 and HDAC2 could be isolated individually (Figure 
3.5 B), demonstrating that this method could be used to screen HDAC inhibitors 
against these individual HDAC isoforms.  
 
A         B 
 
Figure 3.5. Co-IPs of HDAC1 and HDAC2.  Western blot analysis 
(antibodies indicated to the right of figure) of HDAC1 and HDAC2 Co-IPs 
from HeLa lysates; lysate lane is 10% loading of HeLa lysates; control is in 
the absence of antibody; 1 indicates HDAC1 IP; 2 indicates HDAC2 IP.  A) 
IPs performed in the absence of lysate pre-clearing with protein A 
agarose.  B) Lysates pre-cleared with protein A agarose prior to IPs.  
 
 
With a feasible method for isolating HDAC1 and HDAC2 individually, we 
next wanted to isolate each of the human HDAC proteins.  Using the pre-clearing 
method, HDAC proteins were isolated from HeLa lysates using protein A agarose 
resins conjugated to individual HDAC 1-8 and 10-11 antibodies; HDAC9 was not 
detected in the HeLa lysates (data not shown).  Under these conditions, HDAC1 
1 1 2 2 Lysate Lysate Control 
anti-HDAC1 
anti-HDAC2 
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through HDAC7 and HDAC10 have been isolated individually through IP with the 
antibody-conjugated protein A resins (Figure 3.6).  IPs of HDAC8 and HDAC11 
were unsuccessful with the available antibodies, but were detected by western 
blot analysis (see Appendix B.2.2).  Importantly, each isoform could be isolated 
individually, demonstrating that HeLa lysates are an appropriate source of 
individual HDAC isoforms for screening HDAC inhibitors.  With conditions 
established where the individual HDAC isoforms could be precipitated separately 
we worked towards development of an HDAC-dependent ELISA (section 3.2.4). 
 
 
Figure 3.6 HDAC Co-IPs from HeLa Lysates.  Individual HDACs (lanes 
across bottom of gel) were immunoprecipitated from HeLa lysates, 
separated by SDS-PAGE, followed by western blot analysis with 
antibodies indicated to the right (Lys = 10% of input, C = Control, no 
antibody). 
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3.2.4 HDAC-Dependent ELISA 
To establish our HDAC inhibitor assay in a high-throughput format, an 
inhibitor based ELISA is under development.  To our knowledge this is the first 
ELISA assay that relies of small molecule-protein interaction.  For this 
application, 96-well plates coated in secondary anti-rabbit antibody were treated 
with anti-HDAC1 to isolate the individual HDAC1 isoform.  Plates were then 
treated with HeLa lysates containing SAHA-Biotin CID, followed by SA-HRP 
compex, and visualized with an HRP substrate (Figure 3.1).  
First, we established that the assay was dependent on the concentration 
of SAHA-biotin CID B (36) by including varying concentrations of SAHA-biotin 
(Figure 3.7).  The background signal OD450 was observed at around 0.13 with no 
increase in signal observed at 0.01 µM or 0.1 µM (Figure 3.7).  Minor increase in 
signal was observed at 1 µM (OD450 = 0.167), 2.5 µM (OD450 = 0.255) and 5 µM 
(OD450 = 0.305), with significant increase in signal at 10 µM (OD450 = 0.517) and 
20 µM (OD450 = 1.03) concentration of SAHA-biotin CID B (36) (Figure 3.7).  For 
future experiments 10 µM SAHA-biotin CID B (36) concentration was used.   
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Figure 3.7. HDAC1-Dependent ELISA With Varying Concentration of 
SAHA-Biotin CID B (36).  HeLa lysates were treated with varying 
concentration of SAHA-biotin CID B (36) (µM concentrations listed below 
bars) and absorbance of HRP substrate, TMB, was measured at 450 nm.  
Results are the average of two simultaneous trials. 
 
Once we established the dose-dependence of SAHA-biotin CID B (36), we 
next demonstrated the ability to disrupt the system by pre-incubating lysates with 
varying concentrations of competitive SAHA (Figure 3.8).  Similar to the results 
from Figure 3.6, high signal was observed in the ELISA with 10 µM SAHA-biotin 
B compared to the control lane in the absence of CID (Figure 3.8, lanes 1 and 2).  
SAHA was pre-incubated with the HeLa lysates for 10 minutes prior to the 
addition at SAHA-biotin CID B in the last 5 columns (Figure 3.8); a slight 
decrease was observed with an equal concentration of SAHA (10 µM) compared 
to SAHA-biotin CID B alone (Figure 3.8, lanes 3 and 2).  With the addition of 10-
fold and 20-fold excess of SAHA (100 µM and 200 µM) the signal was decreased 
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by about half (Figure 3.8, lanes 4 and 5).  Significant decrease in signal from the 
HDAC-dependent ELISA was observed with 50-fold and 100-fold excess of 
SAHA (500 µM and 1000 µM).  These results provide evidence that the HDAC-
dependent ELISA may be a useful screening tool for competitive HDAC inhibitors 
through disruption of the HDAC-binding to the SAHA-biotin CID. 
 
 
SAHA-biotin CID B (µM) 0 10 10 10 10 10 10 
SAHA (µM) 0 0 10 100 200 500 1000 
 
Figure 3.8. HDAC1-Dependent ELISA With Varying Concentration of 
Competitive SAHA.  HeLa lysates were treated with 10 µM SAHA-biotin 
CID B (36) in the presence of varying concentration of SAHA (µM 
concentrations listed in table below below bars) and absorbance of HRP 
substrate, TMB, was measured at 450 nm.  Results are from a single trial. 
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3.2.5 Conclusions and Future Directions 
The results from the HDAC-dependent ELISA are still preliminary.  Once 
we have established reproducibility and optimized conditions, other HDAC 
isoforms will be used to establish that this assay is applicable for isoform 
selectivity screening.  The assay will then be used to screen competitive small 
molecules other than SAHA to confirm the system is useful for screening a 
variety of HDAC inhibitors.   
 
3.3 Biochemical methods 
3.3.1 General Materials 
 Reagents were generally purchased from Fisher Scientific, Acros Organics 
or Sigma Aldrich unless otherwise noted; Yeast Nitrogen Base without amino 
acids, BactoTM Agar, BactoTM peptone and Yeast Extract were purchased from 
Difco; dried milk was purchased from the grocery store.  
 
3.3.2 General Equipment 
 The Pflum lab is equipped with standard biochemical equipment including 
centrifuges (Eppendorf models 5415D and 5810R), bacterial incubator/shaker 
(New Brunswick Scientific C25 Incubator Shaker Classic Series), a Tecan 
GENios Plus spectrophotometer, a VWR rocking platform, and a Barnstead 
Thermolyne Labquake shaker rotisserie. 
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3.3.3 HeLa Cells Lysis 
 HeLa cells were purchased from Biovest Inc. in aliquots of 1 x 109 cells 
frozen to – 80 °C.  Tubes were lysed by adding 9.0 mL of Jurkat Lysis Buffer 
(JLB; 50 mM Tris-HCl, pH 8.0, 150 mM sodium chloride, 10 % glyercol, 0.5% 
Triton X-100) and 100 µL of 100X Calbiochem protease inhibitor cocktail V 
(catalog number 539137) and rotating at 4 °C for 30 minutes.  The tube was 
thoroughly mixed by pipetting up and down to ensure complete cell lysis.   The 
cell debris was then removed by centrifugation at 12000 RPM at 4 °C for 30 
minutes.  The lysate was then assessed for protein content (mg/mL) using Bio-
Rad protein assay (Bradford reagent, catalog number 500-006).  Hela cell lysates 
from 106 cells in 100 µL of JLB typically contained 5-15 mg/mL.  Aliquots were 
stored at -80 °C and thawed at 4 °C prior to use. 
 
3.3.4 NeutrAvidin Bead Pulldown with SAHA-Biotin CIDs 
Method A. The initial concentration-dependent NeutrAvidin bead pulldown 
experiments were performed using SAHA-biotin CID A (22).  For this 
experiment, 100 µL of HeLa lysates (section 3.3.1 from approximately 106 cells; 
typically 5-15 mg/mL) containing SAHA-biotin CID A (22) (1 µM, 10 µM, or 100 
µM; 1% DMSO final concentration) were added to NeutrAvidin agarose resin (20 
µL of suspended resin, 80 nmol biotin/mL resin, Pierce catalog number 29200).  
The tubes were incubated overnight at 4 °C with rotation.  The following morning 
the resin was centrifuged at 1000 x g for 1 minute, and the liquid was removed by 
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aspiration.  The resin was washed 3 times with cold JLB (1 mL) following the 
same protocol.  SDS loading buffer (10 µL, 50 mM Tris-Cl, 100 mM DTT, 2% 
(w/v) SDS, 0.1% bromophenol blue, 10% glycerol) was added to the resin, which 
was then incubated at 95 °C for more than 60 seconds to disrupt the binding 
interactions.  Samples were then separated by SDS-PAGE electrophoresis 
(section 3.3.7) and analyzed by western blot (section 3.3.9) with primary anti-
HDAC1 from rabbit (1:10,000 in PBST containing 10% dried milk (w/v), 60 
minutes at room temperature; Sigma catalog number H3284) and secondary anti-
rabbit peroxidase (1:10,000 in PBST containing 10% dried milk (w/v), 60 minutes; 
Sigma catalog number A9169).  The western blot for this experiment was 
visualized using SuperSignal® west fempto maximum sensitivity substrate kit 
(catalog number 34094) following the manufacturerʼs instructions. Western blots 
were visualized using a Typhoon 9210 variable mode imager (Amersham 
Biosciences) measuring luminescence. 
 
Method B. The NeutrAvidin bead pulldown experiments were performed using 
SAHA-biotin CID B (36).  For these experiments, NeutrAvidin agarose resin (20 
µL of suspended resin, 80 nmol biotin/ml resin, Pierce catalog number 29200) 
was added to spin columns (Pierce catalog number 69705) and the liquid was 
removed by centrifugation at 1000 x g for 1 minute.  The resin was then washed 
three times with Pierce IP Lysis/wash buffer (200 µL; 25 mM Tris, 15 mM sodium 
chloride, 1 mM EDTA, 1% NP-40 or Igepal, 5% glycerol; pH 7.4), centrifuging 
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after each wash to remove the liquid.  The spin columns were then closed with a 
plug, and 100 µL of 1µM CID solution (1% DMSO in IP Lysis/wash buffer) was 
added to the columns; columns were sealed with screw cap, and incubated 
overnight with rotation at 4 °C.  The following morning the resin was centrifuged 
at 1000 x g for 1 minute to remove the CID solution.  Precleared HeLa lysates 
(100 µL, 5 mg/mL; section 3.4.1) were diluted with Pierce IP Lysis/wash buffer (to 
300 µL), and this solution was added to the CID coated resin.  The spin columns 
were sealed and incubated for 2 hours at 4 °C with rotation.  The lysates were 
removed by centrifugation and the resin was washed three times with Pierce IP 
Lysis/wash buffer (200 µL).  The bound proteins were then eluted from the beads 
by adding 10 µL of elution buffer (Pierce Kit 26147, primary amine, pH 2.8) to the 
spin columns and centrifuged (1 minute at 1000 x g).  The eluent was collected 
into clean 1.5 mL epitubes containing 2.5 µL of 1 M Tris (pH 9.5 to neutralize the 
acidic elution buffer).  An additional 30 µL of elution buffer was added to each 
spin column and incubated at room temperature for 5 minutes, then collected (1 
minute a 1000 x g) into the same epitube as the first elution.  5X SDS loading 
buffer (11 µL) was added to the eluted protein solution and the tubes were 
heated to 95 °C for at least 1 minute.  The samples were then loaded onto SDS-
PAGE gels (section 3.3.7) and analyzed by western blot (section 3.3.9). 
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3.3.5 HDAC1 expression in BL21 E. coli 
 HDAC1 bacterial expression plasmid pET21bHDAC1112 was obtained from 
Paulina Karwowska-Desaulniers, who cloned human HDAC1 into commercially 
available plasmid pET21b (Novagen catalog number 69741-3).112,113  The 
HDAC1 plasmid was transformed into chemocompetant BL21 strain of E. coli 
(prepared following the same method described in section 2.6.3) using the 
protocol described in Chapter 2 (section 2.6.4).  A single colony, selected by 
ampicillin resistance, was seeded in a 5 mL culture of LB media containing 50 
µg/mL ampicillin and incubated overnight at 37 °C, 250 rpm.   The following day, 
0.5 mL of this culture was added to 100 mL of LB media containing 50 µg/mL 
ampicillin, and grown at 37 °C with 250 rpm shaking until the OD600 was around 
0.6 (approximately 3 hours).  IPTG (125 µL of 0.8 M; final concentration 1 mM) 
was added to the culture to induce protein expression, and cells were incubated 
37 °C, 250 rpm for 3 additional hours.  Cells were collected at 4000 rpm for 5 
minutes and the media was removed.  Cells were resuspended and washed with 
cold phosphate buffered saline (PBS; 0.01M sodium phosphate, 0.15 M sodium 
chloride; pH 7. 2) (3 x 10 mL) and collected by centrifugation after each wash.  
The cell pellet was finally resuspended in 4 mL of PBS containing 1 mg/mL of 
lysosyme, and incubated on ice for 30 minutes.  To the cells was added 10 mL of 
0.2% Triton-X 100 and DNAse and RNAse and the tube was shaken vigorously 
followed by a 10 minute incubation on ice. The cell debris was then removed at 
12000 rpm for 30 minutes and the lysate was treated with DTT to a final 
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concentration of 1 mM.  The lysates were then adjusted to resemble JLB buffer 
by adding glycerol (to 10%), Triton-X 100 (to 0.5%), and 10X PBS (to make 1X 
PBS) and final DTT concentration of 0.8 mM.  The lysates were aliquoted and 
stored at -20 °C.  These lysates were then used in the NeutrAvidin CID pulldown 
experiment by combining 50 µL of lysates (from approximately 0.286 mL of cell 
culture) thawed on ice, with 10 µL of suspended NeutrAvidin beads coated in 
SAHA-biotin CID (as described above). 
 
3.3.6 Traditional Immunoprecipitations (IPs) of HDAC1 and HDAC2 
 The initial IPs (IPs) of HDAC2 were prepared by combining 100 µL of 
HeLa lysates (section 3.3.1 from approximately 106 cells) with 2.5 µg of anti-
HDAC2 antibody from rabbit (Sigma catalog number H3145).  The solutions were 
incubated overnight at 4 °C with rotation to allow antibody binding to HDAC2.  
Protein A agarose resin (20 µL of suspended resin, 12-15 mg human IgG/ml 
resin, Pierce catalog number 20333) was added to the antibody-containing lysate 
solution, and the reactions were incubated for 2 hours at 4 °C with rotation.  The 
resin was centrifuged at 1000 x g for 1 minute, and the liquid was removed by 
aspiration.  The resin was washed 3 times with JLB (1 mL) following the same 
protocol.  SDS loading buffer (10 µL) was added to the resin, which were then 
incubated at 95 °C for more than 60 seconds to disrupt the binding interactions.  
Samples were then separated by SDS-PAGE electrophoresis (section 3.3.7) and 
western blot analysis (section 3.3.9). 
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3.3.7 Preparation of αHDAC conjugated Protein A beads 
 IPs of HDAC proteins were performed with the Pierce Crosslink IP kit 
(Pierce catalog number 26147) where the primary antibodies were covalently 
attached to protein A coated agarose beads in the presence of disuccinimidyl 
suberate (DSS).  Following the manufacturerʼs protocol, 20 µL of suspended 
Pierce Protein A/G Plus resin slurry was added to a spin column in a collection 
tube and centrifuged at 1000 x g for 1minute to remove the liquid from the beads 
and then washed twice with 200 µL of PBS.  The columns were tapped on a 
piece of paper towel to remove excess liquid and the bottom plug was inserted.  
100 µL of antibody solution in PBS was added to the beads (specific amounts 
used indicated in Table 3.1) and incubated with agitation at room temperature for 
60 minutes.  After incubation, the plug was removed from the spin column; the 
liquid was removed by centrifugation (as above) and washed 1 x 100 µL PBS and 
2 x 300 µL PBS. The crosslinking solution was prepared by adding 38.5 µL of 
water to the spin columns followed by 2.5 µL of 20X PBS and 9 µL of 2.5 M DSS 
in DMSO.  The solution was then incubated for 60 minutes at room temperature 
with agitation then centrifuged to remove the crosslinking solution (as above).  
The beads were then washed 1 x 50 µL of elution buffer (primary amine solution; 
pH 2.8) and 2 x 100 µL of elution buffer to remove unbound antibody.  The beads 
were then washed 2 x 200 µL of IP Lysis /wash buffer (25 mM Tris, 15 mM 
sodium chloride, 1 mM EDTA, 1% NP-40 or Igepal, 5% glycerol; pH 7.4).  Beads 
were then either used immediately or stored in IP Lysis/Wash buffer (200 µL) for 
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up to 5 days or for longer in PBS (200 µL) with 0.02% sodium azide.  When 
stored in PBS, beads were washed 2 x 200 µL of IP lysis/wash buffer prior to 
use. 
 
Table 3.1.  HDAC Antibody Solutions for Conjugated Protein A Beads. 
HDAC 
Antibody 
Volume 
used (µL) 
Amount 
used (µg) 
Volume 20X 
PBS (µL) 
Volume 
water (µL) 
Source of antibody 
(product number)  
1 1 10.7 5 94 Sigma (H3284) 
2 1 12.4 5 94 Sigma (H3159) 
3 1 13.3 5 94 Sigma (H3034) 
4 10 12.0 5 85 Sigma (H9411) 
5 10 10.0 5 85 Sigma (H9663) 
6 50 10.0 5 45 SCBT (sc-11420) 
7 5 10.0 5 85 SCBT (sc-11421) 
8 12 10.8 5 83 Sigma (H8038) 
10 20 15.4 5 75 Sigma (H3413) 
11 20 22 5 75 Sigma (H4539) 
 
 
3.3.8 Co-Immunoprecipitations (IPs) of HDAC proteins from HeLa lysates 
 Immunoprecipitations were generally done on a scale to load onto 4 gels.  
For a typical experiment HeLa lysates were precleared by adding 2 mg (0.5 mg 
per gel lane) of total protein per HDAC IP to 20 µL of suspended Protein A 
agarose beads and rotated at 4 °C for at least 60 minutes (for 10 HDAC IPs and 
control, 22 mg of HeLa lysates was precleared with 220 µL suspended beads).  
The precleared lysates were then separated from the agarose beads by 
centifugation for 1 minute at 1000 x g, divided into 10 equal volumes, and 
aliquoted into the plugged spin columns containing individual HDAC antibodies 
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conjugated to Protein A beads (described in section 3.3.5).  Spin columns were 
filled to a total volume of 300 µL with the pre-cleared lysates diluted in IP 
lysis/wash buffer and incubated overnight at 4 °C with rotation to allow protein 
binding to antibodies. The following day, the lysates were removed by 
centrifugation  (1 minute, 1000 x g) and the beads were washed 3 x 200 µL of IP 
lysis/wash buffer, and 1 x 100 µL conditioning buffer (Pierce Kit 26147, neutral 
pH buffer), centrifuging to remove liquid after each wash.  The antigen was then 
eluted from the beads with 10 µL of elution buffer (Pierce Kit 26147, primary 
amine, pH 2.8) added to the spin columns and collected (1 minute at 1000 x g) 
into clean 1.5 mL epitubes containing 2.5 µL of 1 M Tris (pH 9.5 to neutralize the 
acidic elution buffer).  An additional 30 µL of elution buffer was added to each 
spin column and incubated at room temperature for 5 minutes, then collected (1 
minute a 1000 x g) into the same epitube as the first elution.   Antibody resins 
were immediately washed 2 x 100 µL of PBS to restore the proper pH, and stored 
in 200 µL or IP lysis/wash buffer or PBS with 0.02% sodium azide (as described 
in previous section); the antibody resins could be reused several times over the 
course of 2 weeks.  The antigen elution solution was then incubated with 5X SDS 
loading buffer (11 µL) and heated to 95 °C for more than 1 minute.  The samples 
were then loaded onto SDS-PAGE gels (as described below); 13 µL of sample 
was loaded into each lane on the gel.  Lysate control lanes were prepared by 
combining 40 µL of lysates (section 3.3.1) with 10 µL of SDS loading buffer and 
heating to 95 °C for 1 minute; 12.5 µL of this solution was loaded onto each gel. 
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3.3.9 SDS-PAGE Electrophoresis 
 Protein samples from NeutrAvidin pull-down experiments and IPs 
(sections 3.3.2, 3.3.4 and 3.3.6) were separated by sodium dodecyl sulfate 
(SDS)-PAGE electrophoresis prior to western blot analysis.  Gels were prepared 
so that the separating layer contained a final concentration of 10% 37:1 
acrylamide/bisacrylamide (Acros catalog number 330225000) by combining (per 
gel) 1 mL of 4X Tris/SDS buffer (0.4% SDS, 1.5 M Tris, 0.24 M HCl; pH 8.8), 1.96 
mL of water, 1 mL of 40% 37:1 acrylamide/bisacrylamide, 40 µL of 10% 
ammonium persulfate, and 2 µL of N,N,Nʼ,Nʼ-tetramethylethylenediamine (Acros 
catalog number 138450500).105  The gel mixture was mixed thoroughly, poured 
(around 3 mL) immediately into a BioRad mini-Protean tetra cell casting module 
and covered with methanol for polymerization.  The stacking layer was then 
prepared by mixing 500 µL of 4X Tris/SDS buffer (as above, pH adjusted to 6.8), 
1.24 mL of water, 250 µL of 40% 37:1 acrylamide/bisacrylamide, 10 µL of 10% 
ammonium persulfate and 1 µL of tetramethylethylenediamine (per gel).  The 
methanol was removed from the polymerized separating layer, and the stacking 
layer was added followed by an appropriate comb.  Once the staking layer was 
polymerized, gels were inserted in the BioRad (Protean III) gel apparatus and 
filled with SDS running buffer (0.1% SDS, 25 mM Tris, 250 mM glycine; pH 8.3).  
Gels were loaded with molecular weight standards and samples using round gel-
loading tips, and run using constant 200 volts for 60 to 70 minutes. 
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3.3.10 Protein Transfer From SDS Gel to PVDF Membrane 
 SDS-PAGE gels were transferred to a polyvinylidene fluoride (PVDF) 
membrane for western blot analysis (Millipore Immobilon-P, 0.45 micron).105  The 
membrane was cut to an appropriate size and soaked in methanol to activate the 
membrane for protein transfer.  The membrane and the gel were assembled 
between pieces of filter paper and padding and inserted into the BioRad 
chamber.  The chamber was filled with CAPS/Methanol buffer made by 
combining 100mL of 10X CAPS buffer (0.1 M CAPS, pH adjusted to 10.5 with 10 
M sodium hydroxide) with 100 mL of methanol and filling to 1 L with deionized 
water.  The protein transfer was performed in the BioRad chamber for 60 to 90 
minutes at constant 90 volts, with an ice pack in the chamber to prevent 
overheating.   After protein transfer was complete the membrane was air dried to 
ensure protein binding to the membrane, and then soaked in methanol before 
western blot analysis. 
 
3.3.11 Western Blot Analysis 
 PVDF membranes were blocked 8 hours to overnight using low fat dry 
milk (10%) in PBS with Tween-20 (PBST, 0.1 % Tween-20).  After blocking was 
complete the membranes were washed 3 x 5 minutes with fresh PBST to remove 
any unbound milk protein.  The primary antibody solutions (10% low fat dry milk 
in PBST containing 0.002% sodium azide as a preservative) varied in antibody 
concentration and incubation time for each individual protein; Table 3.2 
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summarizes the conditions used for primary anti-HDAC antibodies in western 
blotting.  After incubation with the primary antibody, membranes were washed for 
3 x 5 minutes with PBST to remove unbound antibody.  The membranes were 
then coated with a secondary anti-rabbit antibody with a fluorescent label for 
visualization for 60-90 minutes (PBST solution containing 10% low fat dry milk).  
Either DyLight 649 (1:3000, Pierce catalog number 35565) or DyLight 649 light 
chain specific (1:2500, Jackson ImmunoResearch catalog number 211-492-171) 
secondary antibodies were used.  The membranes were washed 3 x 5 minutes 
with fresh PBST to remove any excess antibody, followed by 1 x 5 minutes of 
distilled water.  Western blots were visualized using a Typhoon 9210 variable 
mode imager (Amersham Biosciences) measuring fluorescence at 670 nm. 
 
Table 3.2.  Antibody Solutions for Western Blotting. (For manufacturer 
and product number see table 3.1). 
 
HDAC Antibody Dilution Incubation time 
1 1:10,000 1 hour 
2 1:10,000 1 hour 
3 1:1000 1 hour 
4 1:250 1 hour 
5 1:200 Overnight 
6 1:100 Overnight 
7 1:100 Overnight 
8 1:100 Overnight 
10 1:100 Overnight 
11 1:100 Overnight 
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3.3.12 ELISA Plate Assay 
 The ELISA based plate assay was performed using Pierce Reacti-Bind 
secondary goat anti-rabbit IgG coated plates (catalog number 15135).  Clear 
plates were used for the colorimetric assay in combination with Pierce 1-Step 
Ultra TMB-ELISA horseradish peroxidase (HRP) substrate following the 
manufacturerʼs instructions (catalog number 34028).  Prior to use, wells were 
washed three times with wash buffer (Tris-buffered Saline (TBS, 50 mM Tris-HCl, 
150 mM sodium chloride, pH 7.4) containing 0.05 % Tween-20 and 0.1% bovine 
serum albumin (BSA)).  Wells were washed using a squirt bottle to fill to 
approximately 200 µL, and emptied by inversion. Wells were coated first with 
primary antibody solution (100 µL of 1 ng/mL) for 1 hour at room temperature 
with rocking.  For the anti-HDAC1 (Sigma H3284) antibody, a coating solution 
was made by diluting a solution of 1 µg/mL anti-HDAC1 in water (1:1000) into a 
dilution buffer (wash buffer containing 3% BSA) to give a final antibody 
concentration of 1 ng/mL. Control wells containing no antibody were coated with 
dilution buffer during this period. After the hour incubation period, the plate was 
emptied by inversion and washed 3 times with wash buffer (as above), then 
washed 1 additional time with 200 µL of wash buffer with 5 minutes of rocking 
before the plate was emptied and allowed to drain on paper towel.  The dried 
plates were then coated with the lysate solution and/or SAHA-biotin CID and/or 
competitive HDACi.  The lysate solution was prepared by diluting HeLa lysates 
(usually 5-8 mg/mL) into dilution buffer to a final concentration of 100 µg/mL.  98 
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µL of the lysates solution was added to each well.  Control wells containing no 
lysates were coated with dilution buffer alone. For competitive HDACi treated 
wells, 1 µL of 100X solution of SAHA in DMSO was added immediately to the 
lysate solution, while 1 µL of DMSO alone was added to the other wells.  The 
plate was incubated at room temperature with rocking for 10 minutes to allow the 
competitive HDACi (SAHA) a binding advantage, after which time 1µL of 100X 
SAHA-biotin CID (1 mM to give final concentration of 10 µM) was added; 1 µL of 
DMSO was added to control wells. The plate was incubated for an additional 50 
mintues, then washed with wash buffer (3 x 200 µL) and then with wash buffer 
(200 µL) for 5 minutes with shaking (as above). Pierce Ultra-Sensitive ABC 
Peroxidase staining reagent (catalog number 32050) was prepared 30 minutes in 
advance by combining 27 µL of reagent A (avidin) and 27 µL of reagent B 
(biotinylated peroxidase) in 3 mL of PBS buffer, mixing thoroughly before letting 
stand at room temperature to allow the avidin complex to equilibrate. This ABC 
reagent (100 µL) was added to each well, and incubated at room temperature for 
30 minutes with rocking.  The plate was then emptied by inversion and washed 
as above.   Finally, room temperature Pierce 1-Step Ultra TMB-ELISA reagent 
(catalog number 34028, 100 µL) was added to the plate and incubated until the 
positive control reached an absorbance at OD620 around 0.20-0.25.  The reaction 
was quenched by adding 2M sulfuric acid (100 µL) to all wells and final 
absorbance readings were taken at OD450.  Plates with unused wells were dried 
thoroughly and stored with desiccation at 4 °C.  
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APPENDIX A 
A.1 Suberic Anhydride (3). 
A.1.1 1H NMR  
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A.1.2 13C NMR 
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A.1.3 IR 
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A.1.4 HRMS 
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A.2     8-(benzyloxyamino)-8-oxooctanoic acid (8). 
A.2.1 1H NMR  
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A.2.2 13C NMR 
 
  
  
136 
A.2.3 IR 
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A.2.4 HRMS 
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A.3   2-(4-(8-(benzyloxyamino)-8-oxooctanamido)phenyl)acetic acid (11). 
A.3.1 1H NMR  
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A.3.2 13C NMR 
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A.3.3 IR 
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A.3.4 MS 
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A.4   SAHA fragment (20). 
A.4.1 1H NMR  
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A.5    Estrone Oxime (14). 
 
A.5.1 1H NMR  
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A.5.2 13C NMR 
 
  
145 
A.5.3 IR 
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A.5.4 HRMS 
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A.6   2.1 tert-butyl 4-aminobenzylcarbamate (26). 
A.6.1 1H NMR  
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A.6.2 13C NMR 
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A.6.3 IR 
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A.6.4 HRMS 
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A.7   8-((4-(((tert-butoxycarbonyl)amino)methyl)phenyl)amino)-8-
oxooctanoic acid (29). 
A.7.1 1H NMR 
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A.7.2 13C NMR 
 
  
153 
A.7.3 IR 
  
  
154 
A.7.4 MS 
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A.8 tert-butyl 4-aminophenethylcarbamate (32). 
A.8.1 1H NMR  
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A.8.2 13C NMR 
  
  
157 
A.8.3 IR 
  
  
158 
A.8.4 MS 
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A.9   8-((4-(2-((tert-butoxycarbonyl)amino)ethyl)phenyl)amino)-8-
oxooctanoic acid (33).   
A.9.1 1H NMR  
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A.9.2 13C NMR 
  
  
161 
A.9.3 IR 
  
  
162 
A.9.4 MS 
  EM
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A.10 9H-fluoren-9-yl)methyl 4-aminophenethylcarbamate (37). 
A.10.1 1H NMR  
  
  
164 
A.10.2 13C NMR 
 
  
165 
A.10.3  IR 
  
  
166 
A.10.4 MS 
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A.11 6-(bromomethyl)pteridine-2,4-diamine (47). 
A.11.1  1H NMR 
 
  
168 
A.11.2  13C NMR 
 
  
169 
A.11.3  IR 
  
  
170 
A.11.4  MS 
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A.12 MTX fragment (42). 
A.12.1  1H NMR  
  
  
172 
A.12.2  13C NMR 
  
  
173 
A.12.3  IR 
  
  
174 
A.12.4  MS 
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A.13 SAHA-biotin CID A (22). 
A.13.1 Crude HPLC 
 
A.13.2 HPLC Re-inject 
 
AU
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
2.00
2.20
2.40
2.60
2.80
Minutes
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 34.00
996  at 220.00 - PDA 210.0 to 400.0 nm at 1.2 nm
996  at 254.00 - PDA 210.0 to 400.0 nm at 1.2 nm
AU
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
1.10
1.20
1.30
1.40
Minutes
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 34.00
996  at 220.00 - PDA 210.0 to 400.0 nm at 1.2 nm
996  at 254.00 - PDA 210.0 to 400.0 nm at 1.2 nm
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A.14   SAHA-biotin CID B (36).   
A.14.1 Crude HPLC Method A  
 
 
A.14.2 Crude HPLC Method B 
 
Red line = 214 nm; black line = 254 nm. 
AU
-0.20
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
2.00
2.20
2.40
2.60
2.80
3.00
3.20
3.40
Minutes
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 34.00
996  at 220.00 - PDA 210.0 to 400.0 nm at 1.2 nm
996  at 254.00 - PDA 210.0 to 400.0 nm at 1.2 nm
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A.14.3 HPLC Re-inject Method B 
 
Black line = 214 nm; red line = 254 nm. 
 
A.14.4 HRMS 
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Single Mass Analysis
Tolerance = 5.0 PPM   /   DBE: min = -1.5, max = 150.0
Element prediction: Off 
Number of isotope peaks used for i-FIT = 6
Monoisotopic Mass, Even Electron Ions
2699 formula(e) evaluated with 12 results within limits (up to 50 closest results for each mass)
Elements Used:
C: 0-100    H: 0-1000    N: 0-8    O: 0-9    23Na: 0-1    S: 0-1    
m/z
680.0 682.5 685.0 687.5 690.0 692.5 695.0 697.5 700.0 702.5 705.0 707.5 710.0 712.5 715.0 717.5 720.0 722.5 725.0
%0
100
LCT2008-07b.pro 2010-cif.spl
28-Jun-2011LCT Premier16:04:53
EMILY AUBY                      SAHA B
2011_0628_1992 13 (0.283) Cm (10:18-1:6x2.000) 1: TOF MS ES+ 
2.34e+003
701.3312679.3488
681.3505 686.3241 696.4297 702.3359 717.3031 724.4038723.3144
Minimum:                                    -1.5
Maximum:                  5.0      5.0      150.0
Mass       Calc. Mass     mDa      PPM      DBE      i-FIT      i-FIT (Norm) Formula
679.3488   679.3489       -0.1     -0.1     10.5     17.2       1.1          C32  H51  N6  O8  S 
           679.3485       0.3      0.4      21.5     18.3       2.2          C39  H44  N8  O2  23Na 
           679.3496       -0.8     -1.2     19.5     18.5       2.4          C40  H47  N4  O6 
           679.3472       1.6      2.4      16.5     18.2       2.1          C38  H48  N4  O6  23Na 
           679.3505       -1.7     -2.5     11.5     18.3       2.2          C35  H52  N4  O6  23Na  S 
           679.3471       1.7      2.5      23.5     21.1       5.0          C44  H47  N4  O  S 
           679.3509       -2.1     -3.1     24.5     19.7       3.6          C41  H43  N8  O2 
           679.3465       2.3      3.4      7.5      18.5       2.4          C30  H52  N6  O8  23Na  S 
           679.3512       -2.4     -3.5     20.5     20.2       4.2          C43  H48  N2  O4  23Na 
           679.3519       -3.1     -4.6     16.5     19.6       3.5          C36  H48  N8  O2  23Na  S 
           679.3457       3.1      4.6      18.5     22.6       6.6          C43  H51  O5  S 
           679.3455       3.3      4.9      15.5     19.0       2.9          C35  H47  N6  O8 
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A.15   SAHA-MTX CID (41). 
A.15.1 Crude HPLC  
 
Black line = 214 nm; blue line = 254 nm; red line = 336 nm. 
 
A.15.2 HPLC Re-inject 
 
Black line = 214 nm; blue line = 254 nm; red line = 336 nm 
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A.15.3 HRMS 
 
 
  
Elemental Composition Report                                                                                                                                                                                         Page 1
Single Mass Analysis
Tolerance = 5.0 PPM   /   DBE: min = -1.5, max = 150.0
Element prediction: Off 
Number of isotope peaks used for i-FIT = 6
Monoisotopic Mass, Even Electron Ions
3435 formula(e) evaluated with 16 results within limits (up to 50 closest results for each mass)
Elements Used:
C: 0-100    H: 0-1000    N: 0-15    O: 0-10    23Na: 0-1    
m/z
200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700
%0
100
LCT2008-07b.pro 2010-cif.spl
29-Jun-2011LCT Premier10:17:41
EMILY AUBY                      SAHA M
2011_0629_1994 16 (0.318) Cm (14:18-1:8x2.000) 1: TOF MS ES+ 
1.08e+004
889.4299456.2080309.7941206.0783 551.3553 874.4198696.4266 891.4373 987.5152 1778.86131334.1405
Minimum:                                    -1.5
Maximum:                  5.0      5.0      150.0
Mass       Calc. Mass     mDa      PPM      DBE      i-FIT      i-FIT (Norm) Formula
889.4299   889.4297       0.2      0.2      17.5     32.5       0.9          C40  H58  N12  O10  23Na 
           889.4321       -2.2     -2.5     20.5     33.5       1.9          C42  H57  N12  O10 
           889.4337       -3.8     -4.3     21.5     34.9       3.3          C45  H58  N10  O8  23Na 
           889.4262       3.7      4.2      29.5     36.4       4.8          C49  H53  N12  O5 
           889.4265       3.4      3.8      25.5     36.4       4.8          C51  H58  N6  O7  23Na 
           889.4278       2.1      2.4      30.5     34.7       3.1          C52  H54  N10  O3  23Na 
           889.4289       1.0      1.1      28.5     34.7       3.1          C53  H57  N6  O7 
           889.4302       -0.3     -0.3     33.5     34.0       2.4          C54  H53  N10  O3 
           889.4292       0.7      0.8      24.5     34.8       3.2          C55  H62  O9  23Na 
           889.4305       -0.6     -0.7     29.5     34.3       2.7          C56  H58  N4  O5  23Na 
           889.4316       -1.7     -1.9     27.5     35.6       4.0          C57  H61  O9 
           889.4318       -1.9     -2.1     34.5     34.5       2.9          C57  H54  N8  O  23Na 
           889.4329       -3.0     -3.4     32.5     36.5       4.9          C58  H57  N4  O5 
           889.4342       -4.3     -4.8     37.5     37.6       6.0          C59  H53  N8  O 
           889.4257       4.2      4.7      36.5     39.0       7.4          C64  H57  O4 
           889.4270       2.9      3.3      41.5     37.4       5.8          C65  H53  N4 
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B APPENDIX B 
B.1 Yeast Three Hybrid Raw Data 
B.1.1 SAHA-biotin Y3H 
 
SAHA-biotin trial 1 1 2 3 4 5 6 
No Zymo             
OD600 0.9250 0.8123 0.7196 0.9322 0.8008 0.7974 
OD420 0.0528 0.0705 2.9252 0.0524 0.0767 2.9716 
OD420/(OD600*0.25mL*20 min) 0.0114 0.0174 0.8130 0.0112 0.0192 0.7453 
/lane 1 no zymo (0.0114) (fold) 1.0000 1.5205 71.215 0.9848 1.6779 65.286 
With Zymo             
OD600 0.8342 0.6460 0.6033 0.8426 0.6432 0.5957 
OD420 0.0586 0.0565 2.8726 0.0533 0.0662 2.9663 
OD420/(OD600*0.25mL*20 min) 0.0140 0.0175 0.9523 0.0127 0.0206 0.9959 
/lane 1 no zymo (0.0114) (fold) 1.2307 1.5322 83.416 1.1082 1.8031 87.236 
              
SAHA-biotin trial 2 1 2 3 4 5 6 
No Zymo             
OD600 0.7073 0.5063 0.2348 0.6531 0.4847 0.2664 
OD420 0.0535 0.0559 2.3921 0.0541 0.0601 2.9982 
OD420/(OD600*0.25mL*30 min) 0.0101 0.0147 1.3584 0.0110 0.0165 1.5006 
/lane 1 no zymo (0.0101) (fold) 1.0002 1.4599 134.71 1.0953 1.6396 148.82 
With Zymo             
OD600 0.6525 0.4523 0.2528 0.7143 0.4136 0.2517 
OD420 0.0514 0.0598 2.7637 0.0517 0.0624 2.9976 
OD420/(OD600*0.25mL*30 min) 0.0105 0.0176 1.4576 0.0097 0.0201 1.5879 
/lane 1 no zymo (0.0101) (fold) 1.0416 1.7482 144.56 0.9571 1.9949 157.48 
              
Average 2 trials No Zymo 1.0001 1.4902 102.96 1.0400 1.6588 107.05 
Average 2 trials With Zymo 1.1361 1.6402 113.99 1.0326 1.8990 122.36 
              
pSH 18-34 + + + + + + 
pSA1 SA T7-B42 - + - - + - 
pSH 17-4 - - + - - + 
SAHA-biotin B (100 uM) - - - + + + 
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B.1.2 SAHA-MTX Y3H 
 
SAHA-MTX trial 1 1 2 3 4 5 6 7 8 
No Zymo                 
OD600 0.7409 0.5170 0.6580 0.7428 0.7613 0.4880 0.6342 0.7339 
OD420 0.0641 0.0715 0.0711 1.8278 0.0668 0.0660 0.0755 1.6342 
OD420/(OD600*0.25mL
*60min) 0.0058 0.0092 0.0072 0.1640 0.0058 0.0090 0.0079 0.1484 
/lane 1 no Zymo 
(0.0058) (fold) 1.0000 1.5985 1.2490 28.44 1.0142 1.5632 1.3760 25.738 
With Zymo                 
OD600 0.5184 0.4283 0.4821 0.5436 0.5897 0.4382 0.8289 0.5900 
OD420 0.0786 0.0660 0.0648 1.5753 0.0698 0.0664 0.0727 1.9839 
OD420/(OD600*0.25mL
*60min) 0.0101 0.0103 0.0090 0.1932 0.0079 0.0101 0.0058 0.2242 
/lane 1 no Zymo 
(0.0058) (fold) 1.7525 1.7811 1.5536 33.495 1.3681 1.7514 1.0138 38.866 
                  
SAHA-MTX trial 2 1 2 3 4 5 6 7 8 
No Zymo                 
OD600 0.6731 0.3850 0.4632 0.5497 0.5326 0.4031 0.5872 0.4676 
OD420 0.0534 0.0561 0.0532 1.8484 0.0525 0.0599 0.0559 0.9832 
OD420/(OD600*0.25mL
*50min) 0.0063 0.0117 0.0092 0.2690 0.0079 0.0119 0.0076 0.1682 
/lane 1 no Zymo 
(0.0063) (fold) 1.0000 1.8367 1.4477 42.385 1.2425 1.8731 1.2000 26.504 
With Zymo                 
OD600 0.4970 0.3129 0.4834 0.4385 0.4337 0.2811 0.4430 0.4179 
OD420 0.0519 0.0534 0.0520 1.0696 0.0503 0.0531 0.0574 1.7111 
OD420/(OD600*0.25mL
*50min) 0.0084 0.0137 0.0086 0.1951 0.0093 0.0151 0.0104 0.3276 
/lane 1 no Zymo 
(0.0063) (fold) 1.3163 2.1512 1.3559 30.746 1.4619 2.3811 1.6332 51.611 
                  
Average 2 trials No 
Zymo 1.0000 1.7176 1.3483 35.413 1.1283 1.7182 1.2880 26.121 
Average 2 trials With 
Zymo 1.5344 1.9662 1.4548 32.121 1.4150 2.0663 1.3235 45.238 
                  
pMW 112 + + + + + + + + 
pSA1 HDAC1-B42 - + - - - + - - 
pSA1 RPD3-B42 - - + - - - + - 
p424 HDAC1-VP16-
LexA - - - + - - - + 
SAHA-MTX (100 μM) - - - - + + + + 
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B.2 Duplicate Western Analyses 
B.2.1 HDAC2 Co-IPs 
A           B 
 
 
 
Figure B.1. Western Blot Analysis of HDAC1 and HDAC2 With 
Varying Wash Conditions.  Western blot analysis (antibodies indicated in 
middle of figure) of HDAC1 and HDAC2.  Lane 1: HeLa lysates (10% 
loading); Lanes 2: HDAD2 IP; Lane 3: control no SAHA-biotin CID with 
NeutrAvidin beads; Lanes 4: SAHA-biotin (1 μM) pre-incubated with 
NeautrAvidin beads.  Washing conditions 3 x 1mL JLB varying [NaCl] a) 
150mM; b) 500 mM; c) 1 M; d) 1.5 M; e) 2 M.  Panel A) performed in the 
absence of lysate pre-clearing with protein A agarose (lanes1-2) or 
NeutrAvidin resin (lanes 3-4); panel B) lysates pre-cleared with protein A 
(lanes1-2) or NeutrAvidin resin (lanes 3-4) agarose prior to experiment.  
 
anti-HDAC2 
anti-HDAC1 
1a 2a  2b  2c  2d   2e 3a  4a  4b  4c  4d 4e 1a 2a  2b  2c  2d  3a  4a  4b 4c 4d 
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B.2.2 HDAC Co-IPs 
 
 
Figure B.2. HDAC Co-IPs from HeLa Lysates.  Individual HDACs (lanes 
across bottom of gel) were immunoprecipitated from HeLa lysates, 
separated by SDS-PAGE, followed by western blot analysis with 
antibodies indicated to the right (Lys = 10% of input, C = Control, no 
antibody). IP for HDAC 5 was unsuccessful, as were IPs for HDAC8 and 
HDAC11. 
  
anti-HDAC3 
anti-HDAC5 
anti-HDAC7 
anti-HDAC6 
anti-HDAC10 
anti-HDAC2 
anti-HDAC1 
anti-HDAC4 
Lys   C   1     2     3     4     5    6    7    8   10  
11
anti-HDAC11 
anti-HDAC8 
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B.3 Raw Data For HDAC-Dependent ELISA 
 
C Table B.1. HDAC1-Dependent ELISA With Varying Concentration of 
SAHA-Biotin CID B (36).  HeLa lysates were treated with varying 
concentration of SAHA-biotin CID B (36) (µM concentrations listed below 
bars) and absorbance of HRP substrate, TMB, was measured at 450 nm.  
Results are the average of two simultaneous trials. 
 
[SAHA-biotin B (36)] (μM) HeLa Lysate (ug/mL) OD450 Trial 1 OD450 Trial 2 Average OD450 
5.0 0 0.1303 0.1276 0.1290 
0.0 100 0.1318 0.1396 0.1357 
0.01 100 0.1259 0.1376 0.1318 
0.1 100 0.1260 0.1441 0.1351 
1.0 100 0.1656 0.1680 0.1668 
2.5 100 0.2160 0.2939 0.2550 
5.0 100 0.2682 0.3419 0.3051 
10 100 0.4797 0.5533 0.5165 
20 100 0.9920 1.0685 1.0303 
 
 
 
Table B.2. HDAC1-Dependent ELISA With Varying Concentration of 
Competitive SAHA.  HeLa lysates were treated with 10 µM SAHA-biotin 
CID B (36) in the presence of varying concentration of SAHA (µM 
concentrations listed in table below below bars) and absorbance of HRP 
substrate, TMB, was measured at 450 nm.  
 
 [SAHA-biotin B (36)] (µM) [SAHA] (μM) HeLa Lysate (ug/mL) OD450 Trial 1 
10 0 0 0.2452 
0 0 100 0.0788 
10 0 100 1.7475 
10 10 100 1.6334 
10 100 100 0.9346 
10 200 100 0.7995 
10 500 100 0.2690 
10 1000 100 0.1521 
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ABSTRACT 
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Histone Deacetylase (HDAC) proteins are transcriptional regulators that 
affect histone proteins, which are involved in packaging of DNA into 
chromosomes.  HDACs have been linked to the proliferation of cancer through 
their role in transcriptional regulation.  Due to these findings, HDAC inhibitors 
have been explored as anti-cancer agents. Several HDAC inhibitors are currently 
in various stages of clinical trials, and the inhibitor suberoyl anilide hydroxamic 
acid (SAHA) has been FDA approved for treatment of cutaneous T-Cell 
lymphoma.  Currently, most of the known HDAC inhibitors are non-selective, 
which causes non-specific binding to the active sites of all HDAC isoforms, 
including those not involved in cancer. To date, screening for HDAC inhibitors 
has been done using an in vitro fluorescence-screening assay, which is unable to 
test for selectivity.  Alternatively, HDAC inhibitors are screened against 
commercially produced proteins, which is very time consuming and can be 
prohibitively expensive.  To improve the screening methods for HDAC inhibitors, 
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we are developing an assay to screen HDAC inhibitors against individual 
isoforms in a high-throughput assay.  The assay has been developed using a 
competitive bifunctional small molecule based on SAHA to test for inhibitor 
binding.   
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